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Effective drug therapy requires an adequate dosage control that can 
control the plasma concentration to be in between Maximum Tolerated 
Concentration (MTC) and Minimum Effective Concentration (MEC). 
The conventional drug administration methods fail to achieve effective 
drug therapy. Therefore, localized drug delivery devices have been 
devised to overcome the shortcomings of systemic drug administration, 
oral gavage and intravenous injection. 
Localized drug delivery devices realize spatial control simply by 
installing it on desired sites. Challenges of drug delivery devices are 
precise control of dosage, exact time of release, and low power 
consumption. All of these can be achieved by controlling the actuation 
components of the device: microvalves and pumps. The proposed device 
utilizes a balloon-like inflatable and deflatable drug reservoir, which 
eliminates the use of a pump. Moreover, a normally closed magnetically 
actuated microvalve that requires power consumption only when it opens 
was constructed. Consequently, the device was designed to release drug 
substances driven by the tension and stress formed by the inflated drug 
chamber only upon the actuation of the microvalve. 
Conventional PDMS patterning methods introduced in Micro 
Electromechanical Systems (MEMS) include photolithography and 
etching. Previous methods, however, require several steps and long 
processing time. A novel PDMS patterning method that only employs 
vapor deposition, oxygen plasma treatment, and stencil screen-printing 
was devised for simpler and faster procedure. 
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Vapor deposition of trichlorosilane is a commonly used method to 
coat a barrier between PDMS layers from bonding. In the contrary, 
oxygen plasma treatment is a method used to bond layers of polymerized 
PDMS. Coordinating the two methods, along with a polyvinyl chloride 
(PVC) stencil patterned using a cutting plotter or a diode pumped solid-
state laser, selective bonding was implemented. Selective bonding of 
PDMS accounted for the formation of the drug reservoir and the pump. 
Moreover, inhibition of PDMS polymerization was exploited over PVC 
substrates to acquire results similar to PDMS etching. This new etching 
alternative was used to construct microchannels with widths ranging 
from approximately 200 to 1000 micrometers. These microchannels with 
varying cross-sectional area served as a secondary drug release rate 
regulator. 
A magnetically actuated microvalve consist of two components. The 
opening mechanism of this normally closed valve was driven by an 
external magnet that produces magnetic field and a circular magnetic 
membrane with a neodymium magnet bonded on the surface with PDMS 
that deflects towards the external magnetic source. All the component of 
the microvalve were fabricated using only PVC stencils and PDMS-
metal powder composites. Nickel powder-PDMS composite was used for 
the deflection membrane. 
The completed device was evaluated on biocompatibility for 
implantation and durability for reusability. PDMS may be biocompatible, 
PDMS-metal powder may show different results. In the device, even 
though PDMS-metal powder composites were encapsulated with pure 
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PDMS, long-term use may increase cytotoxicity. Moreover, surface 
modification using trichlorosilane and oxygen plasma may also have an 
adverse effect on biocompatibility. Therefore, the device was tested for 
biocompatibility using elution and cell growth evaluation. Furthermore, 
the device was intended to be refillable and reusable. Thus, the durability 
of the microvalve and the inflatable chamber was evaluated by actuating 
the valve multiple times and whether or not the mechanical characteristic 
changed over the experiment. 
 
Keywords : Polyvinyl Chloride (PVC) Stencil Patterning, 
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Multiple Layer PDMS Patterning, Conductive PDMS Polymer, 
Localized Drug Delivery Device 
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Microfluidics grew into versatile technological applications since its 
advent in the 1990’s: fluid mixing and separation, miniaturized sensors, 
lab-on-a-chip devices etc. [1]-[10]. These devices are normally fabricated 
using conventional Micro Electromechanical System (MEMS) 
fabrication methods. Through conventional Micro Electromechanical 
System (MEMS) fabrication procedures such as photolithography, 
deposition, and etching, the devices normally use polydimethylsiloxane 
(PDMS) for its biocompatibility, chemical compatibility, flexibility, easy 
fabrication, and optical transparency [11], [12]. Microfluidics developed 
into the drug delivery field as fabrication methods progressed to have 
higher resolution and a capability to build complex multi-layer designs. 
 
Figure 1-1. Therapeutic range drug delivery devices should aim for: 
between Maximum Tolerable Concentration (MTC) and Minimum 
Effective Concentration (MEC). 
 
Therapeutic drug delivery requires adequate amount of drug release 
 
 ２
to maintain a plasma concentration to a level between Maximum 
Tolerated Concentration (MTC) and Minimum Effective Concentration 
(MEC). Conventional drug administration methods, systemic and local, 
reach highest concentration shortly after injection. The duration of action 
of administered drug starts as soon as the concentration rises above and 
stops as it falls below MEC. Purpose of effective drug therapy is to 
prolong this duration as long as possible. However, oral and injection 
methods’ concentrations rapidly decrease [13]. Consequently, higher 
dosage or periodic administration is necessary. Higher dosage can 
increase the risk of cytotoxicity and periodic administration may be 
problematic. Therefore, considerable efforts have been devoted towards 
developing ‘smart’ advanced drug delivery systems to realize effective 
drug therapy [14]-[16]. 
 
1.1. Drug Delivery Device in Microfluidics 
 
Recently, various novel drug delivery platforms have been developed 
to target sites to improve the outcome of the treatment process [17]. 
These devices can be categorized into micro, nanoparticle size drug 
carriers made of biodegradable material [18]-[20] and localized drug 
delivery device by their mechanism on how they achieve spatial control 
[21]-[23]. 
Drug carriers generate reproducible release profile by encapsulating 
drug substances with degradable or withstanding materials in certain PH 
or temperature [24], [25]. For example, orally administered drug carriers 
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must survive pass through the low PH of the gastrointestinal tract to be 
released into the blood stream. Moreover, they have to be small enough 
to be able to pass through the intestinal mucosal barrier. Fabrication of 
drug carriers [17], [19], [20], self-assembly [26]-[30], droplet-based, 
non-spherical [31]-[37] etc. is plausible by recent advances in 
development of microfluidic systems. Drug carriers, like any other drug 
delivery devices, should adjust release rate, improve bioavailability, and 
reduce cytotoxicity. 
Localized drug delivery devices realize spatial control by directly 
installing the device onto desired sites. Therefore, only temporal control 
is required. Microfluidic systems allow precise handling of nano-liter and 
pico-liter volumes. More importantly, these systems can be programmed 
to release a certain amount, which can be accurately reproduced 
assuming constant conditions. This direct delivery characteristic 
facilitates the use of drugs with short half-life or those that may be toxic 
when systemically administered. 
 
1.2. Localized Drug Delivery Device 
 
Localized drug delivery devices can be subcategorized into various 
types such as drug loaded polymeric devices and microfluidic 
implantable devices [38]. Drug loaded polymeric devices utilize 
diffusion or biodegradability of the composing material. Due to these 
release mechanisms, these devices have a few shortcomings. Drug 
release begins delivery as soon as drug is loaded in the device for devices 
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that utilize diffusion. For biodegradable devices, release begins when the 
device reaches a certain environment, PH, heat, or elapsed time [24], [25]. 
For localized drug delivery devices that utilized biodegradability, release 
initiates when they are installed on chosen locations. 
The localized drug delivery devices focused in this paper are 
implantable microfluidic devices controlled by convective forces such as 
magnetic [40], [41], electromagnetic [42], [43], [49], electrostatic [44], 
[45], osmotic [46]-[48], and pneumatic [39], [50] etc. These devices are 
different from diffusion or degradation-based devices in that they are 
designed to be responsive to convective forces, therefore, which enable 
on demand drug delivery. Furthermore, release rate can also be controlled 
which has its advantage of diffusion-based delivery platforms with 
continuous and non-uniform release profile. 
Microfluidic local drug delivery platforms are usually comprised of a 
drug reservoir, a pump, a valve and a microchannel [51]. The simplest 
design of these various platforms employ a mechanical pump and a valve 
that pushes and opens by an outside trigger: magnetic [40], [41], 
electromagnetic [42], [43], [49], electrostatic [44], [45], thermal [52], etc. 
Here, microchannels lie between other components such as valves and 
drug reservoirs not only connecting them, but also guiding drug flow to 
precise locations. Recently developed localized drug delivery devices 
attempt to simplify the design by eliminating crucial components such as 
pumps or valves. Since pumps and valves in this device are power-
consuming components, reducing these components not only simplifies 
the design, but also reduces overall power-consumption. 
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While spatial control of drug delivery devices are realized by fixing 
the device on desired sites, temporal control is relatively more difficult. 
Temporal control can be achieved actively or passively. Polymeric 
devices that manipulate biodegradability and diffusion are passive 
devices. As mentioned above, passive devices fail to deliver exact 
quantities of drug to target sites. Active control can amend these 
shortcomings of passive control systems. These systems allow on 
demand drug administration and precise drug quantification in response 
to external stimuli such as electric or magnetic fields. However 
promising these systems may be, several challenges still remain.  
Micrometer-scale pump, channel, well, and valve fabrication 
technologies have been developed yet integrating them to build a single 
system is challenging. 
 
1.3. Microvalves and Pumps in Microfluidic Drug 
Delivery Devices 
 
Many types of miniaturized microvalves and pumps for lab-on-a-
chip have been developed. Different types of actuation and modes exist 
in valve and pumps. To be applied on lab-on-a-chip devices, several 





Figure 1-2. Microvalves with various actuation mechanisms. a), b), c) are 
active microvalves and d), e), f) are passive microvalves. a) electro-
active nanovalve array reusable for drug delivery [53]. b) thermos-
pneumatic actuator valve for a blood test system [66]. c) 
electromagnetically actuated valve for glaucoma implant [54]. d) Passive 
check valves actuated piezoelectrically [69]. e) Full polymeric micro 
check valves [74]. f) Micromachined passive valve fabricated through 
polycrystalline silicon [70]. 
Microvalves can be categorized initially by active [53]-[68] and 
passive [69]-[79]. These passive and active microvalves can be further 
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categorized into their actuation originality. Passive and active 
microvalves can be subcatergorized into mechanical and non-mechanical 
components. Mechanical active microvalves are accomplished using 
conventional MEMS-based micromachining technologies where 
mechanically moveable membranes or components are coupled to 
magnetic, electric, piezoelectric or thermal actuation. Non-mechanical 
active microvalves actuate due to their functionalized smart materials 
such as phase change or rheological materials. Passive microvalves can 
also be classified into mechanical and non-mechanical categories. 
However, passive microvalves are regarded as micropumps since there is 
no fine line between them considering their actuation mechanism [80]-
[82]. Microvalves can also be divided into their initial mode: normally 
open [67], [83]-[85] and normally closed [68], [86]-[87]. The design of 
the microvalve determines the initial mode. Normally closed mode 
requires energy consumption only when it needs to be opened. Normally 
open mode requires energy only when it needs to be closed. Therefore, 
normally closed mode is more desirable for it requires less energy 
consumption. 
Typical operation range of micropumps lies in between a few 
microliters to tens of microliters. Micropumps can also be classified into 
mechanical and non-mechanical pumps. Mechanical pumps utilize 
moving parts such as check valves, oscillating membranes, or turbines 
for delivering a constant fluid volume in each cycle. Non-mechanical 
pumps add momentum to the fluid for pumping effect by converting 
another energy form into kinetic energy. All micropumps, mechanical or 
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non-mechanical, require energy consumption. 
With the energy consumed in the microvalve and the micropump, 
installing a power source large enough to handle them both on a localized 
drug delivery device is difficult for its millimeter-size device. Therefore, 
localized drug delivery devices must minimize the power consumption 
throughout the device. 
 
1.4. Polydimethylsiloxane (PDMS) Etching 
 
PDMS is a polymeric material used in a variety of fields for its 
biocompatibility, chemical resistance, optical transparency, flexibility, 
and ease in fabrication. Its innate ability to convert from liquid form to 
solid form just by applying heat makes it so prevalent over other 
materials used in similar fields.  Conventional MEMS fabrication 
methods such as spin coating, photolithography, several surface 
modification techniques are commonly used methods to produce 
patterned PDMS [88]-[92]. However, there are also some drawbacks. 
Since the polymerization process of PDMS is irreversible once PDMS 
solidifies, re-patterning is possible only with certain defects or 
shortcomings. Moreover, PDMS is frequently used to replicate by 
developing hard molds. Therefore, only single layer patterning is 
possible. Consequently, complex designs with multiple layer fabrication 
can only be realized by bonding fully polymerized PDMS layers. In this 
process, difficulties rise in handling thin layers of patterned PDMS and 





Figure 1-3. Previous PDMS etching methods. a), b) are PDMS etching 
using high powered CO2 laser [95]. c) is an image of PDMS dry etching 
using only fluorine based reactive ion etching [96]. d) is fabrication steps 
for PDMS etching by combination of wet and dry etching [97] 
. Patterning polymerized PDMS can be plausible by a few methods: 
direct laser cutting, wet and dry etching. High-powered laser such as CO2 
laser or Diode Pumped Solid State (DPSS) can be used to cut out grooves 
on fully polymerized PDMS [93]-[95]. Since patterning is achieved by 
burning off polymerized PDMS, the resulting surface is not smooth 
enough and microscale residue may be difficult to wash off. Dry and wet 
etchings of PDMS are also fabrication methods that can pattern fully 
polymerized PDMS. Dry etching is performed by fluorine-based reactive 
ion etching (RIE) [96]. Regulating the gas ratio between oxygen and 
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tetraflouromethane can control the etching rate of RIE. Relatively simple, 
however, the procedure demands long hours of processing time just to 
etch a few tens of micrometers of PDMS and is incapable of meeting 
precise amount of etching depth. The process produces significant 
surface roughness, which is inadequate for microfluidic applications. Wet 
etching of PDMS is a type of chemical etching [97].  A mixture of 
tetrabutylammonium fluoride (TBAF) and n-methyl-2-pyrrolidion 
(NMP) with a ratio of 1:3 can melt off PDMS on contact areas. However, 
severe undercutting is unavoidable due to lateral etching. Moreover, 
PDMS that has undergone chemical etching process does not sustain the 
physical and chemical characteristics of normal PDMS. Complete 
removal of microscale, even nanoscale residue or arbitrary patterns on 
PDMS surfaces caused by wet and dry etching is vital since they can 
cause turbulent fluid flow in microchannels. Furthermore, both wet and 
dry etchings require photo-resistive hard baked patterns developed by 
photolithography prior to the etching process. This does not only increase 
steps in developing photoresist patterns, but also steps in removing 
photoresist patterns after PDMS etching. 
 
1.5. PDMS Surface Modification: Hydrophilic 
Alteration 
 
PDMS polymerization starts with mixing PDMS pre-polymer with a 
curing agent in 10:1 ratio. After mixing and degassing for uniformity, 
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PDMS is spin coated onto a silicon wafer or a patterned surface. PDMS 
takes on a liquid form before it undergoes hydrosilylation process. 
Therefore, spin coating and replica molding is easily achievable. The 
hydrosilylation process solidifies liquid PDMS into solid PDMS, which 
can be accelerated with the aid of heat stimuli. Fully polymerized PDMS 
preserves its advantageous characteristics such as biocompatibility, high 
chemical resistance, optical transparency etc., however, gains one crucial 
disadvantage inadequate in biomedical applications: hydrophobicity. 
Hydrophobicity of native PDMS hinders bonding between PDMS and 
other materials such as glass, silicon and other PDMS, disrupts liquid 
delivery and decreases the possibility of proteins or cells from binding to 
the surface. 
In recent years, there have been many PDMS surface modification 
methods such as plasma treatment, silanization, ultraviolet treatment, 
chemical vapor deposition (CVD), layer-by-layer (LBL) deposition, 
metal and metal oxide coatings, partial curing methods, suspended gel 
methods, protein absorption, graft polymer coating and hydrosilylation-
based surface modification [98], [99]. Many of these methods require 
multiple steps and long processing time. Oxygen plasma treatment is the 
most common method used to enhance hydrophilicity of PDMS. 
However, oxygen plasma treated surfaces starts reverting back to 
hydrophobic state minutes after treatment. A more permanent method 
increasing hydrophilicity of PDMS surfaces is silanization. Silanization, 
also known as Self Assembled Monolayer (SAM) coating, is normally 
used to rende PDMS surfaces superhydrophobic. Unlike oxygen plasma 
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treatment, SAM coatings form covalent bonds on the surface of PDMS, 
thus, the modification is permanent. Therefore, a combination of these 
two procedures can achieve moderately hydrophilic PDMS surfaces.  
Oxygen plasma treatment is commonly used to bond two 
polymerized PDMS together. On the other hand, silanization builds an 
anti-bonding layer on the surface so that PDMS replica molding on 
PDMS mold can be realized. Here, an adequate mixture of oxygen 
plasma treatment and silanization using trichlorosilane was used to 
increase hydrophilicity, increase adhesiveness, and bonding. 
 
1.6. Circular Cross-sectional Microchannels 
 
The conventional method of fabricating microchannels produces 
channels with rectangular cross-sectional areas. Whereas, these 
rectangular cross-sectional channels may be used for fluid mixing and 
separation, they are inadequate for biomedical and microfluidic 
applications. In microfluidic applications, viscous fluid flow through 
rectangular microchannels produce a laminar flow where the velocity 
ranges from zero at the walls to highest towards the center of the channel. 
Due to the rectangular shape, when the laminar flow reaches equilibrium, 
the velocity around the four corners of the channel is zero and fluid there 
remain untouched. However, circular cross-sectional microchannels do 
not have corners where residual fluid remains. Therefore, for biomedical 





Figure 1-4. Circular PDMS microchannel fabrication methods. a) [100] and b) 
[101] are thermal reflow methods utilized to develop PDMS microchannels. c) is 
an image of molds fabricated through micromilling [102]. All these methods 





Figure 1-5. Circular microfluidic channel fabrication method using sacrificial 
templates by inkjet printers [103] and sugar templates [104].  
 
Previously developed circular cross-sectional microchannel 
fabrication methods employ conventional MEMS fabrication methods: 
photolithography patterning with thermal reflow [100], [101], and 
micromilling [102]. The typical fabrication methods produce two open 
semi-circular cylinders where the two are bonded to construct a 
cylindrical channel. Since the constructed channels are tens or hundreds 
of micrometers thick, alignment to realize perfect cylindrical shape is 
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very difficult. Many novel circular cross-sectional microchannel 
fabrication methods have been devised. An inkjet printer was used to 
pattern microchannels on pre-polymerized PDMS bath. The ink printed 
on the PDMS bath was then immersed. PDMS was then polymerized and 
the ink was removed [103]. Another example of a novel circular cross-
sectional microchannel fabrication was by a sugar printer [104]. A three 
dimensional structure was printed using a 3D printer that uses sugar 
filaments. The structure is then immersed in a PDMS bath and 
polymerized. Similarly, the structures can be easily oxidized or melted 
through to construct microchannels. Both methods are examples of 
fabricating circular cross-sectional microchannels. However, both 
methods produce slightly dented circular channels due to the softness of 
the filaments or the ink used. 
 
1.7. Flexible Conductive PDMS 
 
Conductive line fabrication over rigid surfaces is achievable using 
conventional MEMS fabrication methods. Deposition, photolithography 
patterning, and etching steps are required to accomplish lift-off processes 
to pattern metals. Most of these metal conductive lines are deposited over 
hard substrates such as silicon wafers and glass plates for several reasons. 
Flexible materials such as PDMS, polyimide, parylene, etc. have weak 
adhesion to metal substances [105]. However malleable metals may be, 
deposited metal on PDMS and parylene easily tear off. Moreover, metals 
cannot stretch like polymeric materials. When metal-coated PDMS is 
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bent, deposited metals crack and disconnect. Consequently, considering it 




Figure 1-6. Stretchable conductive PDMS using silver and CNT particles. 
a) [106], b) [107], c) [106] silver PDMS composites used with metal 
stencils or SU-8 mold. d) Carbon nanotube conductive PDMS designed 
using polymeric molds [125]. 
Alternative conductive line fabrication methods on flexible 
polymeric materials have been devised. A composite of conductive 
particles with polymers were investigated and tested. Silver, nickel, 
copper, iron, nano, microparticles, and carbon nanotubes (CNT) [125] 
were mixed with PDMS in several different weight ratios to manufacture 
conductive lines on polymeric devices [106], [107], [123]. These 
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conductive lines were mounted on other polymeric flexible substrates. 
However, since the mixture contains PDMS, an insulating material, high 
conductivity was difficult to achieve. Higher ratios of conductive powder 
can be a solution to increase the conductivity. However, as the volume 
ratio goes over 25% of conductive powder to PDMS the mixture 
becomes too slurry consequently raises difficulties in molding into 
desired shapes [106], [107]. 
Another drawback in applying PDMS and metal particle composite 
to developing conductive circuit on PDMS substrate is the unreliability 
of composite mixing method. Conductivity of PDMS-metal powder 
composite is determined by the uniform distribution of particles in the 
PDMS solution. Manual mixing fails to achieve uniform distribution and 
thus results in inconsistent conductivity [106], [107]. 
 
1.8. PDMS Adhesion  
 
PDMS has received attention because it is stretchable and flexible. 
Consequently, PDMS is appropriate for attaching onto surfaces like skin 
and implanting into the body. However, completely polymerized PDMS 
has hydrophobic surface properties. Thus, attaching and securely fixing a 
PDMS based device on skin or implanting into a body requires an 
additional adhesive layer fabrication step. 
In previous studies, securely fixing biomedical devices such as 
electrodes and drug delivery devices onto hydrophilic and hydrophobic 
surfaces was realized by applying tape [108], polymeric adhesives, or 
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sutures [109]. Using tape has been the easiest method many biomedical 
devices utilize. However, using tapes leaves a messy result. Therefore, 
using tapes were only implemented on prototype testing. Polymeric 
adhesives that are used mainly on bandages have also been used to 
position devices. The adhesives are pre-manufactured and have a rather 
thick profile to it. The adhesives can be easily cut using blades or scissors. 
Manufacturing and mounting onto fabricated devices is simple. Recently, 
adhesive PDMS (Dow Corning, MG7-9900) was also used to increase 
adhesiveness to paste on the epidermis [110]. Suturing device onto skin 
or organs has also been investigated [109].  Localized drug delivery 
devices are invasive in their nature. Suturing is not only invasive but it 
also increases discomfort to the subject. Furthermore, retrieving the 
device requires an additional invasive procedure. Also, a biomimetic 
approach to realize adhesion of PDMS on hydrophilic and hydrophobic 
surfaces has been investigated. A physical characteristic inspired by 
geckos and mussels were tested [111]. Mussel-mimetic polymer coated 
micropillar fabrication was implemented to increase adhesion. The 
increase in adhesion of biomimetic micropillars remains a controversy, 
still. 
Previously developed adhesive methods and materials all have 
simple fabrication processes. However, the manual process results in a 
messy and sloppy implementation of the device. Moreover, these 
methods increase bulkiness to the device and long-term biocompatibility 




1.9. Previously Developed Drug Delivery Devices 
 
In this subsection, drug delivery devices available commercially, or 
in its research level are investigated. Fabrication methods, composition, 
actuation methods, drug delivery rates, advantages, disadvantages etc. 
were analyzed to compare the results with the proposed drug delivery 
device.  
 
1.9.1. Electro-actively Controlled Thin Films [112] 
This active control drug delivery device utilizes electroactive thin 
films actuated by the presence of a small-applied voltage of 1.25 V. This 
drug delivery device is an example of a layer-by-layer release actuation 
device. These electroactive films, also known as Prussian Blue (PB), are 
nontoxic, FDA-approved inorganic hexacyanoferrate compound. 
Fabrication of the device is rather simple. A glass substrate is coated with 
a conducting film of indium tin oxide (ITO). This is then dipped in a 
solution containing a cationic drug or drug carriers then rinsed with 
deionized water. Next, the substrate is dipped in an aqueous PB solution 
and again rinsed with deionized water. This process is repeated many 
times to build a layer-by-layer profile of drug/drug carriers and 
electroactive particles. Deconstruction of the films is initiated when an 
electrochemical potential of 1.25 V is applied. PB particles switch to the 
neutral Prussian Brown (PX) state and destabilize the film to release the 
encapsulated drug components. 
This device runs on low voltage. The low power consumption of the 
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device increases its potential applicability to implantable pharmacy-on-a-
chip applications. The device can be easily switched on and off by 
applying and disconnecting the power source. Experimental results show 
no release of drug substances while no voltage is applied. The device 
releases micrograms of drug substances or carriers, as a localized drug 
delivery device should. For the device to activate and release micrograms 
of drug substances, however, voltage has to be applied for minutes. 
When voltage is applied, drug release rate rapidly increases. However, 
drug release does not “switch off” when applied voltage is removed. A 
few minutes is required for the electroactive films to stop releasing drug 
substances. 
 
1.9.2. Drug Release Control through Microchannel 
Configuration [113] 
This drug delivery device is designed to deliver drug loaded 
nanoparticles through microchannel configuration with the pressure 
gradient of fluid flow. Delivery rate of nanoparticles is determined by the 
maximum number of nanoparticles in the outlet region after a certain 
time limit. Drug release rate can be regulated through different 
nanoparticles sizes and different microchannel configurations. Nano-
particles is also advantageous in that they can easily cross tissue barriers.  
This device was designed to be applied for an ocular drug delivery 
device that utilize PLA (Polylactide) to deliver bFGF or Rh-6G to the 
retina. From the drug delivery device mechanism explained above, it can 
be induced that the device is a passive drug delivery device with no 
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apparent microvalve that enables the device to actively deliver drugs. In 
other words, drug release begins with the device's installment and the 
ends with the drugs emptying the reservoir. This drug delivery device, 
like many other passive devices, required rather long response time until 
nanoparticles reached the outlet region. Moreover, due to the pressure 
driven fluid gradient, as the release started depletion of the reservoir was 
achieved rather quickly. In other words, the release rate increase rather 
steeply with respect to time.  
 
1.9.3. Frequency Controlled Wireless Hydrogel 
Microvalve [114] 
This active drug delivery device is a polyimide based. The 
fabrication requires polyimide films, polyimide liquid prepolymer, 
copper conductive lines, and hydrogel microvalves made of poly-(N-
isopropylacrylamide) (PNIPAM). The fabrication process requires 
photolithography with the usage of photomasks, and electroplating of 
copper and titanium. This device utilizes microvalves made of hydrogels 
responsive to heat activated by resonant radio frequency. These hydrogel 
microvalves that cover the cavities are thermally actuated through the 
copper conductive lines that release heat when actuated by its resonant 
radio frequency. These hydrogel microvalves are designed to be normally 
closed. To decrease the response time of these hydrogel microvalves, 
they were designed to be small and thin. Therefore, the overall thickness 
of the device was approximately 1 mm. However, to increase the volume 
storage of liquid drug substances, the device inevitably required a broad 
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profile. By using heaters actuated by resonant frequency, the device 
could be stimulated wirelessly. The hydrogel microvalves achieved 38% 
shrinkage at a temperature of 20 degrees Celsius. This drug delivery 
device successfully demonstrates on-demand release with wireless 
actuation which is a critical characteristic an implantable device must 
acquire. However, the resonant frequency mechanism of the device’s 
actuation method required minutes of response time. Moreover, the 
experiment did not specify the release rate of the device itself. However, 
the device merely locks the drug chamber with a hydrogel valve with no 
other pumping mechanism that pushes substances out of the chamber. 
Consequently, the release rate of the device would highly depend on the 
density of the surrounding material. 
 
1.9.4. Magnetically Controlled MEMS Device [115], 
[116] 
This drug delivery device is an active device that realizes temporal 
control by magnetic actuation. The device merely consists of a 
cylindrical reservoir with 6 mm in diameter and 550 m depth sealed 
with a thick surrounding of PDMS opened only at the top. A thin 
magnetic PDMS (iron oxide nanoparticle-PDMS composite) covers the 
top of the reservoir. This magnetic PDMS has thickness of approximately 
40 m with an aperture of approximately 131.7 m in diameter. The 
releasing mechanism is also simple. Magnetic field either induced by an 
external coil or a permanent magnet from the bottom of the device pulls 
the magnetic PDMS membrane towards the reservoir. The membrane 
 
 ２３
pulls toward the drug substances in the reservoir subsequently pushing 
substances out of the reservoir through the aperture in the membrane. As 
simple as the overall process of the device, the fabrication method is 
relatively simple, too. 
Photolithography was implemented to develop the reservoir. On a 
different wafer, magnetic PDMS was spin coated with a sacrificial layer. 
Merely bonding the two with drug loaded in the reservoir and drilling a 
hole with a UV laser completes the device. 
The device is developed using only PDMS and PDMS composites 
which guarantee biocompatibility. Each actuation with an external 
magnetic field releases a few microliters of substances filled in the 
reservoir. From the properties mentioned above, some disadvantages can 
be deduced. First, the device does not have a valve that locks the device’s 
aperture which inevitably results in minor leakage of substances. Second, 
magnetic field originating a few millimeters away from the device can 
only deflect the membrane to a few hundred micrometers. In other words, 
the device cannot completely deplete the reservoir. Moreover, the device 
can only withhold tens of micro-liters, hundred microliters at most. 
Lastly, magnetic field must originate from the bottom of the device. 
Consequently, the orientation of the device is a crucial factor in the 
device’s actuation mechanism. 
 
1.9.5. Electrochemical Intraocular Drug Delivery 
Device [117] 
This drug delivery device is developed for incurable ocular diseases 
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such as retinitis pigmentosa, age-related macular degeneration, diabetic 
retinopathy and glaucoma. All these diseases are incurable and absence 
of treatment may lead to blindness. This active drug delivery device 
utilizes parylene bellows that act as a micropump. This parylene based 
micropump is sealed, filled with DI water and inserted in the drug 
reservoir. Pump electrodes are positioned under this micropump which 
induce electrolysis in the parylene pump. Electrolysis of water results in 
volume expansion due to phase change of liquid substances to gas. Drug 
substances are then released from the reservoir through the cannula with 
the volume change of the pump.  
This device has centimeter scale overall size. Intricate layers of 
MEMS fabrication methods such as photolithography, deposition, and 
lift-off are executed. Moreover, alignment and bonding using epoxy is 
required. Above all, for the precise drug release of the parylene pump, 
the device has a rather rigid base. This rigid profile of the device is a 
major drawback since the device was intended to be implanted in the eye. 
0.2 mA to 1 mA was applied to the electrodes for actuation and 2 L/min 
to 6.5 L/min release rate could be achieved. However, the actuation 
response relied on the electrolysis chemical reaction. Therefore, minutes 
of actuation time was required. More importantly, when the electrodes 
were turned off, the parylene pump slowly returned to its normal shape. 
With the actuation of the device, the drug reservoir already released a 
certain amount. Consequently, when the device is turned on, the device 
will not release substances from the reservoir until the pump reaches the 
volume before the actuation was turned off. This active device requires 
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longer processing time as the reservoir depletes to release consistent 
amounts.  
  
1.9.6. Electrostatic Valve with Thermal Actuation 
[118] 
This implantable drug delivery device is designed to release 
vasopressin, a peptide hormone synthesized in the hypothalamus and 
stored, secreted in the posterior pituitary. Administration of vasopressin 
induces changes in the arterial blood pressure. This administration may 
have no effect on healthy individuals. However, for patients in 
hemorrhagic shock, administrating vasopressin can be a critical 
mechanism for restoring blood pressure. This condition requires precise 
dosing and rapid delivery. This device utilizes gold electrode pads that 
are positioned below and above the pyramid shaped reservoir. This 
reservoir can hold up to 15 L of substances and is covered and locked 
by a thin gold membrane. An electric potential is applied to the 
electrodes that induce electrochemical reactions. Gold membrane that 
locks the reservoir dissolves and the electrolysis of water in the reservoir 
develops microbubbles that consequently propel drug contents in the 
reservoir out. Apparently, higher electrostatic potential applied to the 
electrodes results in faster and higher dose of drug release. However, 
once the gold membrane dissolves, it cannot be restored. Therefore, the 





Figure 1-7. Drug delivery devices in development or in research level. a) 
Electrochemically actuated drug delivery device for ocular delivery [116]. 
b) Drug delivery device with hydrogel microvalves controlled via 
wireless actuation [114]. c) Passive drug delivery device utilizing drug 
loaded nanoparticles controlled through microchannel designs [113]. d) 
Electrostatically actuated drug delivery device where the actuation 
compensates for both valve and pump [117]. e) Magnetically actuated 
drug delivery device that release drugs from the reservoir through 
deflecting flexible membrane [115]. f) Magnetically actuated drug 
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delivery device for prostate cancer [116]. 
 
1.9.7. Transdermal Delivery through Microneedles  
[119] 
Transdermal delivery that offers a number of advantages such as 
improved patient comfort, sustained release, avoidance of gastric 
irritation, and elimination of pre-systemic first-pass effect [118]. 
However, only a handful of medications can be delivered through the 
skin with therapeutic amounts. Many types of microneedles exist and are 
in development. 
Hollow microneedles can be easily fabricated using the 
commercially available 30 gauge hollow needles. Polyetherentherketone 
mold [122], polylactic acid (PLA) sheet [123], polyimide resin [124] 
were used to hold the hollow needles in a array. Other materials such as 
silicon microneedles were also used for their biocompatibility. However, 
silicon needles are too fragile and require high production costs. To 
compensate for the fragility of the silicon needles, sputter deposition of 
titanium and gold were also considered. The fragility of the needles was 
amendable, however, the overall production cost of the device increase 
with the presence of extra deposition steps. Stainless steel microneedles 
are also widely used. Hollow microneedles are rather invasive, however, 
have advantages in delivering substances directly into the epidermis or 
the dermis by penetrating through the stratum corneum. Moreover, 
substances with high molecular weight such as proteins, oligonucleotides, 
and vaccines can also be delivered. Hollow microneedles would be 
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desirable if they had adequate mechanical strength and bores that do not 
clog while transdermal delivery. However, the hollow microneedles in 
development and commercially available still need research to meet these 
requirements. Solid microneedles are made of silicon, metal and 
polymeric materials. These systems delivery drug via passive diffusion. 
Not only drugs, solid microneedles show promising results in delivering 
vaccines. These microneedles are designed to be a few hundred 
micrometers thick to penetrate the stratum corneum. Dissolving 
microneedles are of great interest for a number of advantages. Above all, 
one-step application which is convenient for patients. These 
microneedles are made of polysaccharides or other polymers. Most of 
these dissolving microneedles are made using micromolding. Pouring 
polysaccharides or polymers in female molds and curing under 
centrifugation or pressure.    
There are many advantages of various types of microneedle arrays 
listed above. However, there are still disadvantages of these devices. 
Transdermal delivery requires penetration through stratum corneum into 
the dermis. This method can raise local inflammation and skin irritation 
for patients with allergy or sensitive skin. Moreover, the needles are 
designed to be much thinner than the normal hair. Hollow microneedles 
or coated microneedles can break off while removing the device. 
 
1.9.8. Osmotic Drug Delivery Devices [120] 
Osmotic micropump based drug delivery devices require no 
additional power consuming stimulus consequently are applicable in a 
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variety of fields. Osmotic pumps consist of three compartments: osmotic 
agent, solvent, and drug. In contrast to common tablets or drug injection, 
these systems provide long-term and constant release in either implanted 
in desired sites or systemic way. These systems can handle drug 
substances in solid and liquid form. First osmotic pumps were developed 
more than 50 years ago. Recently, osmotic pump based drug delivery 
devices are commercially available, and are under active development. 
Here, some of commercially available osmotic drug delivery  
The fundamental principle of osmotic pump is generated by two 
solutions with different solute concentrations separated by a semi-
permeable membrane. Through osmosis, solvents from lower 
concentration travel across the permeable membrane to high 
concentrated solution. This applies to the fabrication of osmotic drug 
delivery device. There are devices with one, two, and three 
compartments. For one compartment osmotic device, drugs are stored in 
a chamber with semi-permeable membrane. Solvents, for example bodily 
fluids, travel across this membrane dissolving drugs that later leaves the 
device through the outlet. One compartment osmotic devices’ release 
rates depend on the physical properties of the drug. Two compartment 
osmotic devices have a chamber filled with drug substances and another 
chamber with osmotic agents. These two chambers are divided with a 
movable barrier. As solvents travel in to the osmotic agent chamber and 
expand in size, the barrier moves toward the drug chamber physically 
pushing out drug substances through the outlet. Through this 
compartmentalization, drugs stored in the drug chamber have little 
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limitations. Main drawbacks of two compartment devices are 
complicated design, and reduced drug storage compared to one 
compartment devices.  
 
1.9.8.1. ALZET® [130] 
This commercially available osmotic drug delivery device is 
probably the most prominent example until today. This device is 
designed and fabricated for research purposes by DURECT Corp., 
Cupertino, CA, USA. This device can be implanted in multiple animal 
species as small as mice in multiple anatomical sites. This cylindrically 
shape device is comprised of a collapsible reservoir made of 
impermeable thermoplastic hydrocarbon elastomer which is surrounded 
by a coating layer of osmotic driving agent. The device’s geometry 
minimizes diffusive release or accidental spill and ensures constant 
delivery solely controlled by osmosis. Water enters the osmotic layer 
generating pressure in the drug chamber which then pushes stored drug 
out of the device. Three different sizes with chambers with 100 L, 200 
L, and 2 mL and delivery rates ranging from 0.11 L/h to 10 L/h. This 
device can be operated for 1 day to 6 weeks depending on the device 
choice. A catheter can be connected to the release orifice of the device 
which then can specifically target organs or tissues.  
 
1.9.8.2. DUROS® [131] 
This osmotic drug delivery device is developed by ALZA 
Corporation, Mountain View, CA, USA in 2001. The device is very small 
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comparable to a size of a matchstick and made of titanium alloy. One 
side of this cylindrical device incorporates a semi-permeable membrane 
while the other side has an outlet port. Osmotic agent and drug 
substances are divided with a movable piston. The fluidic substances 
pass through the semi-permeable membrane pressurizing the osmotic 
chamber slowly moving the piston toward the drug chamber. This then 
effectively push drugs out of the chamber through the outlet port. This 
outlet port can also be connected to a catheter to specific sites. Drug 
release can be maintained for a time period of 3 to 12 months. The device 
has overall device dimensions of 4 mm in diameter, 44 mm in length and 
has a drug reservoir of 155 L. This device has been applied to many in 
vivo studies along with toxicity and safety tests. This device was used in 
many long-term clinical trials that managed chronic conditions, pain 
therapy, diabetes mellitus, obesity etc.  
 
1.9.8.3. BuccalDose [132]-[134] 
This disposable osmotic drug delivery device was specifically 
designed to treat Parkinson’s disease. Advanced stages of Parkinson’s 
disease have a narrow therapeutic window which consequently require 
frequent intake of drug whether it is administered orally or invasively 
using a syringe. This device was designed to release constant amounts of 
dopamine agonists to the buccal mucosa and subsequently to the 
bloodstream. The device is implanted in the mouth attached to the gums. 
Once the device is attached to the gums, disposable drug cartridges can 
be easily attached and removed from the device repeatedly. These 
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cartridges contain micro injection molded housing made of cyclic olefin 
copolymer, semi-permeable polyamide thin film, hyperelastic styrenic 
copolymer barrier that separates drug and osmotic agent, and fluidic 
capillaries for drug release. Neodymium cubic magnets are embedded in 
the cartridges for easy attachment and detachment.  
 
Figure 1-8 Osmotic drug delivery devices. a) Release mechanism of drug 
osmotic drug delivery devices with one or two compartments. b) 
BuccalDose intraoral drug delivery device. c) ALZET® drug delivery 




Table 1-1. Comparison of currently in development or commercially available drug delivery devices 
Journal or Device Year Reservoir 
Volume 
Pump Rate Power  Material Composition Disadvantages 




1.25 V Prussian Blue 
Electroactive Film 
Indium Oxide  
Slow response time  
 
Morimoto et al.  
[50] 
2016 Max 1mL 25~45L 
/min 
No power PDMS/Parylene 
PEGDA floating valve 
Passive delivery 
Inconsistent release 
Dispense rate decrease rapidly 
over time 








Slow response in on and off 
 
Pirmoradi et al.  
[115] 
2011 15.7 L 2.1~3.3 L 
 
Magnetic field PDMS  
Magnetic PDMS (iron 
oxide particle) 
Inconsistent dispense rate 
Reservoir is too small, after 5 to 
6 deliveries 
Non refillable/non reusable 
Gensler et al.   
[117] 
2010 100 L 2 L/min to 
3.4 L/min 
Electrolysis 0.2 










Different release rate according 
to magnetic field (magnet 
distance) 
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Table 1-2 Comparison of currently in development or commercially available drug delivery devices 
 
Journal or Device Year Reservoir 
Volume 
Pump Rate Power  Material Composition Disadvantages 















Instant release of the reservoir at 
once 
ALZET® [130] 2000 100L, 
200L,  
2 mL 
0.11 L/hr ~ 
10 L/hr 
Osmotic pump Thermoplastic 
hydrocarbon elastomer 




DUROS® [131] 2001 155 L  Osmotic pump Titanium Casing 
 
Small but rigid device 
Passive delivery 
BuccalDose [133] 2011  1.85 ± 0.02 
L /hr 




copolymer (SEBS)  
Saliva secretion is crucial for 
osmosis 





1.10.  Summary 
 
 
Figure 1-9. Components of the drug delivery device separated layer by 
layer.  
 
Drug administered through oral gavage and syringe injection fails to 
achieve therapeutic drug delivery since sustaining the plasma 
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concentration in between MEC and MTC requires consistent and 
periodic administration. Moreover, the typical administration has a 
systemic effect on the user. To prolong effective drug therapy, 
administering larger doses of drugs or periodic injection may be a 
solution. However, larger doses of drugs may increase the cytotoxicity 
and periodic administration is challenging. Therefore, an increase in 
usage and demand of localized drug delivery devices to substitute 
conventional drug administrating methods such as invasive syringes and 
oral gavage is imminent. 
Localized drug delivery devices achieve both temporal and spatial 
control relatively simply. Spatial control is realized by installing the 
device on locations drug delivery is required directly. Temporal control is 
accomplished by its actuation mechanism. Since the device has to be 
implanted, several conditions have to be met. The device must maintain a 
small profile, be flexible, and be less invasive when it is fixed onto skin 
or other organs to assure patient’s comfort. Localized drug delivery 
devices usually comprise of a drug reservoir, pump, and a valve. 
Furthermore, these components require a power source. All these 
components and the actuation power source have to fit in a miniature 
device. Therefore, the device was designed to consume minimum power. 
For the device to be implantable, only biocompatible materials must be 
used. 
The drug delivery device proposed in this paper attempts to realize 
all the requirements listed above. Firstly, the device uses a mechanical 
pump that does not require a power source. Utilizing oxygen plasma 
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treatment and vapor deposition onto PDMS surfaces, selective bonding 
of PDMS and zero-volume chamber fabrication is realized. Zero-volume 
chambers have flexible walls that have no volume when the chamber is 
empty. When the internal pressure increases via input substances through 
a syringe, the chamber expands. The output mechanism of the device is 
implemented using an output microchannel that connects the chamber 
and the microvalve. This normally closed valve remains closed when no 
external stimulation is present. When the valve is actuated to open via 
electromagnetic actuation, the chamber would deflate and push out 
loaded drug substances through the chamber outlet. Secondly, to 
minimize power consumption, a secondary pump is in necessary. This 
drug delivery device with one inflatable chamber inevitably pumps drug 
substances exponentially. The chamber pumps with higher release rate 
when the chamber is full. The release rate rapidly decreases with respect 
to time. Therefore, consistent drug release and periodic administration of 
drug substances through this device with one pump can be difficult to 
achieve. A secondary pump is used to revise this weakness. A 
microchannel is constructed to connect the chamber with the secondary 
pump. The primary chamber fills the secondary pump to a certain limit. 
When the valve opens, for a couple of seconds, the secondary pump is 
depleted releasing drug substances into the medium. This process can be 
repeated until the primary chamber depletes or reaches a saturation state 
where it cannot further pump substances into the secondary pump. By 
integrating the secondary pump to the primary chamber relatively 
consistent drug amounts could be released. Lastly, a combination of 
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PDMS and microparticles were employed to fabricate magnetically 
responsive PDMS membrane and conductive PDMS composite designs 
that compose the electromagnetically actuated microvalve. These 
composites were used to preserve the flexibility and fabrication 
simplicity of the device. 
The proposed device was designed to be implanted in the body or 
adhered on the skin. The device is PDMS based. However, microparticles 
such as nickel and silver were used. Therefore, the device’s 
biocompatibility required analysis. The completed device was tested for 
in vitro quantitative and qualitative cytotoxicity according to 














2. Materials and Procedures 
 
In this chapter, materials and fabrication procedures required to 
construct the proposed drug delivery device. The fabrication method 
proposed in this thesis eliminates the usage of conventional MEMS 
procedures such as photolithography, wet and dry etching. Instead, 
patterning and fabrication of microstructures were executed by only 
using processes such as spin coating, oxygen plasma treatment, vapor 
coating and designed polyvinyl chloride (PVC) adhesives that substitute 
the function of photomasks.  
 
2.1. System Overview 
 
The proposed drug delivery device consists of four components: 
primary drug chamber, secondary drug pump, release rate controlling 
microchannel, and an electromagnetically actuated microvalve. Many 
drug delivery devices’ working mechanisms have issues in releasing 
consistent amount of drugs until the reservoir is completely depleted. 
Most of them release larger amounts when the reservoir is completely 
full. As the chamber drains, the device actuation either requires longer 
actuation time or stronger power to release consistent amounts. The 
proposed device realizes consistent delivery through the secondary pump. 
Both the primary chamber and the secondary pump are inflatable and 
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deflatable. They inflate as fluidic substance fills up increasing the 
internal pressure and deflate as the substance leaks out from the chamber. 
A microchannel connects the primary chamber to the secondary pump. 
Fluidic drug substance is filled in the primary inflatable/deflatable drug 
chamber via a syringe. As the primary chamber fills up, drug substance 
slowly fills the secondary pump. The secondary pump is filled until a 
certain threshold, determined by their size and thickness of the primary 
reservoir and the secondary pump. When the microvalve opens via 
electromagnetic actuation, the secondary pump starts to drain first. 
Subsequently, the inflated thin membrane of the secondary pump returns 
to its normal shape. Once the secondary reservoir depletes, the 
microvalve is closed. Slowly the secondary pump is filled again through 
the primary chamber. This process can be repeated until the primary 
chamber completely drains. The device delivers relatively consistent 
amount each time the microvalve opens. 
The conventional PDMS microstructure fabrication process includes 
PDMS patterning via photoresist lithography and etching. This process 
produces rectangular shaped microstructures with fixed width and height. 
Therefore, a new fabrication method was necessary to develop the 
components of the device. Here, a non-lithographic approach was taken. 
A combination of oxygen plasma treatment, silanization, and polyvinyl 
chloride (PVC) stencil masks were used to develop each component. 
Utilizing stencils designed and cut using a Diode Pumped Solid State 
(DPSS) laser system, the proposed procedure introduces a novel PDMS 
fabrication method that produce flexible PDMS structures that can 
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change its shape and size in response to the internal pressure. 
 
2.2. Materials 
2.2.1.  Polydimethylsiloxane (PDMS) 
 
 
Figure 2-1. Chemical formula and structure of fully polymerized PDMS 
 
PDMS is one of many silicone polymers frequently used in various 
biomedical applications. It has its prevalence over other polymers in 
optical transparency, biocompatibility, easy fabrication, and good 
mechanical and chemical characteristics. Furthermore, PDMS has 
Young’s Modulus of approximately 1.0MPa which is relatively similar to 
body tissues such as nerves, muscles and brain. Thus, implantation onto 
those tissues is plausible. Aside from these numerous advantages, there 
are a few challenges PDMS has to overcome to be perfectly suitable for 
biomedical applications such as multi-electrode array (MEA) for brain 
machine interface (BMI) applications, and localized drug delivery 
device: low surface energy and chemical stability. 
Low surface energy, hydrophobicity, of PDMS may be its critical 
flaw that raises a couple of problems when PDMS is put into use for 
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MEMS fabrication. PDMS is fabricated by mixing a curing agent 
(Sylgard® 184B, Dow Corning, USA) to liquid pre-polymer (Sylgard® 
184A, Dow Corning, USA) in a 1:10 ratio. PDMS sustains a hydrophilic 
solution even with the curing agent mixed. When heat stimulus is applied 
to the mixture, the hydrosilylation reaction begins with the platinum 
catalysts abundant in the solution form ethylene bond between silicon 
hydrides and silicon vinyl. When the hydrosilylation reaction is complete, 
PDMS attains a solid form with high flexibility and optical transparency. 
However, the process renders the surface hydrophobic. Hydrophobicity 
of PDMS raises issues in many applications due to the incompatibility 
with other metal materials. For example, implantable MEA’s developed 
using PDMS require high adhesion between PDMS surfaces and 
conductive channels to acquire strong signal and increase durability. 
However, deposition of gold directly over PDMS forms weak adhesion. 
Therefore, patterning through photolithography and etching is impossible. 
To ensure strong adhesion between PDMS and metals, a series of surface 
treatment procedures are necessary []. Furthermore, in some cases 
surface treatment does not ensure strong adhesion. Therefore, titanium 
deposition before gold deposition can also be performed. In other cases, 
to increase hydrophilicity of PDMS surfaces oxygen plasma treatment 
and vapor coating can be implemented. 
 
2.2.2.  Polyvinyl Chloride Adhesive Sheets 
Fabrication processes devised here eliminates the usage of 
photolithography, and etching. Subsequently, photo-masks and acidic 
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etching solutions are unnecessary. Rather, photo-masks and etching 
solutions were substituted using PVC adhesive sheets. Two types of PVC 
sheets with different thickness were used: 80 m (Matte PVC, Silhouette, 
USA) and 150 m (Inductive Tape, Taeyoung Chemical Inc. Co. LTD., 
Korea) thick sheets. PVC sheets are widely produced and used synthetic 
plastic. PVC sheets are very versatile and cost-effective thermoplastic 
material that has good dimensional stability, good impact strength and 
excellent weathering properties. PVC sheets can be easily extruded, 
calendered, and cut using a sharp blade. Depending on the composition, 
these sheets can be manufactured in a variety of colors, and even 
transparent. Above all, depending on the thickness of the sheets, they can 
be rigid or flexible. PVC adhesive films commonly refer to flexible films. 
These flexible PVC films were used in this thesis. This flexible nature of 
PVC films is essential to the proposed fabrication method because it 
allows the films to be easily transferred and removed to and from PDMS 
surfaces. Similar to photo-mask preparation, PVC stencils were designed 
using AutoCad program. These designs were cut out using two types of 
machines. A blade plotter (Silhouette Cameo, Silhouette, USA) that uses 
a sharp blade to cut out the PVC stencils. This blade plotter device works 
very much like an inkjet printer. With two step motors each controlling 
the horizontal and vertical movement of the blade, it cuts out the designs. 
The preciseness of the blade plotter differed relative to the cut out speed 
of the blade movement. The other device is the Diode Pumped Solid 
State (DPSS) laser cutter. This laser system (Samurai UV Marking 
System, DPSS Lasers Inc., USA) uses UV lasers at 355 nm. This system 
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was designed to be a marking system. However, by controlling the power 
of the laser, the system could also execute UV ablation and engravings 
on many materials such as wires, metals, sapphire, glass, silicon wafers, 
plastics, paper, polyimides, etc. This ablation property of the system 
could also cut PVC stencils. With the adequate power and wavelength, 
the PVC adhesives could be precisely cut. Both devices used in the 
procedure were analyzed to evaluate the preciseness and accuracy of the 
device. 
PVC sheets have a chemical formula of (C2H3Cl)n. PDMS 
polymerization process relies on the platinum catalyst induced 
hydrosilylation process. This process cross-links silicon hydride with 
vinylsiloxane groups with the aid of platinum catalysts abundant in the 
solution. There has been an experiment conducted to inhibit this 
polymerization process by immobilizing the platinum catalyst which in 
result hinders the hydrosilylation process. Amine group was coated over 
a glass plate which acted as a chelating agent that trapped the platinum 
atoms [129]. Platinum atoms have positive charge. Hence, this positive 
atom binds to the negatively charged amine group. However, inhibition 
also depended on the thickness of the PDMS. Similarly, this inhibition 
process was reproduced by other possible chelating agent. Here, PVC 
stencils were used as chelating agent to reproduce this phenomenon. 
Similar to the negatively charged amine group, PVC sheets can act as a 
chelating agent due to the negatively charged chloride atoms in PVC 
stencils. The negatively charged chloride atoms in PVC stencils attract 
platinum atoms consequently resulting in the inhibition of 
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polymerization of PDMS. Similar to the reaction in [129], the inhibition 
process depended on the thickness of the PDMS deposited over the PVC 
stencils.  
 
2.2.3.  Magnetic Microparticles and Neodymium 
Magnet 
Nickel microparticles were used in this paper to manufacture 
magnetically actuated PDMS membranes. PDMS normally act as an 
inductor. It is non-conductive and non-responsive to magnetic fields. For 
this polymeric material to be responsive to magnets or magnetic fields 
induced by conductive coils, the precured liquid PDMS needs to be 
mixed with metal microparticles. 
There are many magnetic microparticles in use for MEMS 
fabrication. Iron oxide particles, nickel particles, copper particles, 
neodymium particles, etc. Since the proposed drug delivery device is 
designed to be biocompatible for in-body implantation or skin adhesion, 
copper particles are inadequate. Therefore, nickel, iron oxide, and 
neodymium particles were tested and analyzed whether the particles 
cause any problems during the fabrication process. Nickel powder (APS 
2.2-3.0 micron, 99.9% (metal basis), S.A ≈ 0.68 m2/g, Apparent density = 
0.5-0.65 g/cm2, USA), iron oxide (Fe3O4) powder (5 micron, 99%, US 
Research Nanomaterials, Inc., USA), and neodymium (NdFeB) 
microparticles (150m, Xin Chang, China) were used. PDMS has high 
tensile strength and flexibility. Depending on the composition of PDMS 
and metal microparticles, the tensile strength and flexibility of can 
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change accordingly. The higher the composition of the microparticles are 
the tensile strength and flexibility of the film decreased. 
Neodymium magnets are also used in this device. Tensile strength of 
magnetic PDMS membrane fabricated through nickel or iron oxide 
particles is greater than PDMS itself. In this paper, membrane deflection 
of this magnetic PDMS was tested through magnetic actuation and 
electromagnetic actuation. However, due to limited power consumption, 
electromagnetic actuation could not produce enough power to deflect the 
membrane. PDMS’s tensile strength, Young’s Modulus, is thickness 
dependent as the thickness increases over 200 m [126]. Magnetic 
PDMS’s tensile strength does not change if the composition is less than 
10% volume percentage [127]. Magnetic membrane with 162 m 
thickness with 6 mm, 8 mm, 10 mm, diaphragm could be deflected 
approximately 96 m, 141 m, 251 m, respectively, using a permanent 
magnet. Therefore, for magnetic actuation via a permanent magnet, the 
magnetic PDMS could be used for releasing substances. However, for 
electromagnetic actuation, a millimeter size neodymium magnet was 
used for releasing substances. Here, magnetic PDMS was also used for 
fast recovery to lock the microchannel. 
 
2.2.4.  Silver Microparticles and Silver Ink 
Both silver powder (APS 4-7 micron, 99.9% (metal basis), S.A. 0.1-
0.4m/g, USA) and silver ink (Elcoat, Jin Chemical, Korea) were tested to 
develop conductive PDMS composites. This silver ink is composed of 
60~70% silver mixed into ethyl lactate 20~30%. The ethyl lactate is there 
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for ease in application so that it can be used as paint. Many PDMS based 
electronic devices such as flexible sensors, and multi-electrode arrays 
(MEA) require conductive lines. These conductive lines, whether the 
device is biocompatible or not, are made out of gold, silver, lead, etc. The 
conventional gold, silver, and lead conductive lines lack durability in 
many aspects. As the lines become thinner, they become more flexible. 
However, with increased flexibility, the lines are more susceptible to 
crack when they are stretched. Moreover, as mentioned earlier, metal 
deposition over PDMS is challenging due to the lack of hydrophilicity of 
PDMS surfaces. However, bonding between fully polymerized PDMS 
and uncured liquid PDMS is rather simple. PDMS is hydrophilic before 
polymerization and hydrophobic after polymerization. When pre-cured 
PDMS solution is poured over fully polymerized PDMS, the two build 
into one PDMS slab. Therefore, PDMS mixed with other metal particles 
can easily be dispensed over the surface with high adhesion strength. 
Above all, due to the PDMS in the conductive mixture, the conductive 
lines produced using this mixture inherits the flexibility of PDMS. Yet, 
the flexibility and stretchability depends on the composition of the 
mixture. 
As mentioned earlier, there are many conductive microparticles used 
and applied in MEMS fabrication methods. There is nickel, silver, gold, 
iron oxide, copper, etc. Again, copper particles were not adequate for 
they are non-biocompatible. Other materials can also be used. Here, 
however, silver was used because silver has highest conductivity among 
all the other microparticles. Since PDMS is an insulating material, to 
 
 ４８
achieve high conductive lines with PDMS-microparticle composite, 
metal particles with high conductive properties were necessary. 
 
2.3. Procedures 
2.3.1.  Spin Coating 
Spin coating is a commonly used MEMS fabrication method. This 
procedure produces thin films with uniform thickness. Usually, silicon 
wafers are placed on a chuck and securely fastened with a pump. Small 
amounts of spin coating materials are dispensed on the center of the 
substrate. The substrate then spins the substrate, silicon wafer, at a 
programmed speed. Due to the centrifugal force produced by the 
spinning motion, the dispensed material spreads over the surface of the 
substrate developing a uniform thickness. The thickness of the material is 
determined by the rotating speed, time and viscosity of the material itself. 
In some cases, the surface energy of the substrate itself and the dispensed 
solvent’s hydrophilicity and hydrophobicity also has an effect on the 
thickness of the result. 
Fabrication process of the proposed drug delivery device utilizes 
spin coating of PDMS on various substrates with different surface energy. 
PDMS is spin coated over PVC adhesives, silanized wafer, silanized 
PDMS, and oxygen plasma treated PDMS. The thickness of PDMS spin 
coated over each substrate was investigated. Through the results depicted 
through the experiment, the relationship between PDMS thickness and 




2.3.2.  Oxygen Plasma Treatment 
Two types of surface treatment procedures are used. Figure depicts 
the chemical formula of PDMS. This chemical formula presents PDMS’s 
physical characteristics. The methyl group abundant in the PDMS surface 
decreases the attractive force, thus results in low surface tension. These 
are reasons to why PDMS has low surface tension, and low surface 
energy hence combination with other metallic materials is challenging. 
However, surface modification of PDMS is rather simple. Oxygen 
plasma treatment, silanization, and HEMA (2-hydroxyethyl 
methacrylate) processes are frequently used procedures that render the 
surface’s hydrophobicity. In this paper, only oxygen plasma treatment 
and vapor coating trichlorosilane will be used. 
Plasma is one of four state of matter. Under normal conditions, only 
solid, liquid and gas exists. Solid is the state of matter with lowest energy. 
With increase energy induced to the subject, the state of matter changes 
from solid to liquid to gas. Plasma cannot exist under normal conditions. 
Plasma can only be artificially generated by subjecting neutral gas to 
strong electromagnetic field to a point where the ionized gas become 
electrically conductive. In MEMS fabrication, this plasma generation 
process is used for plasma etching, and Plasma Enhanced Chemical 
Vapor Deposition (PECVD). Oxygen plasma treatment or etching is 





Figure 2-2. Oxygen plasma treatment of PDMS surfaces. 
 
Oxygen plasma treatment renders PDMS surface hydrophilic. The 
methyl groups abundant on PDMS surfaces are substituted with hydroxyl 
groups and carboxyl groups through oxygen plasma treatment. 
Consequently, the surface energy increase and the surface is now 
hydrophilic. Moreover, oxygen plasma treatment not only renders the 
surface hydrophilic, but also increases adhesion strength, too. For this 
reason, oxygen plasma treatment can also be used to bond PDMS to 
other substrates such as other PDMS, glass or silicon wafer. However, 
hydrophilic modification through oxygen plasma treatment is not 
permanent [121]. Hydrophobic recovery of plasma treated PDMS begins 
in a matter of minutes. The time it takes for full recovery differs due to 
several aspects such as oxygen concentration, RF power, and treatment 
time. In most cases, PDMS fully recovers its hydrophobicity after several 
days. Volatile modification of PDMS surface energy alone is not 
adequate for the selective bonding process required to fabricated the 
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proposed drug delivery device. However, selective bonding is 
implemented by executing a series of oxygen plasma treatment and 
silanization. Moreover, oxygen plasma treatment was also used as a 
bonding mechanism permanently adhering fully polymerized PDMS 
structures. 
 
2.3.3.  Silanization (Self-Assembled Monolayer) 
Vapor coating using trichloro (1H, 1H, 2H, 2H-tridecaflfluoro-n-
octyl) silane is a type of self-assembled monolayer (SAM) coating over 
polymeric surfaces. SAM coating is a process that bonds one molecular 
thick layer of material to the surface in a manner that satisfies with its 
physical or chemical forces during deposition. Above all, SAM coating is 
different to oxygen plasma treatment in that the process does not bear 
volatile rendering of surface modification. SAM coated PDMS surface 
can be permanently rendered hydrophilic. SAM coating is not necessarily 
implemented to increase hydrophilicity of PDMS surfaces. SAM coating 
is implemented over molds, especially PDMS, for easy peel-off of 
polymerized PDMS from the mold. PDMS is hydrophobic when it fully 
polymerizes. Moreover, if uncured PDMS is poured over fully cured 
PDMS, the two form an irreversible bond. For the mold to successfully 
act as a mold, newly poured uncured liquid polymer must be easily 
removable. Therefore, if PDMS molds are treated with SAM coating, the 
surface can be rendered hydrophilic. Hence, when new PDMS is poured 
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over the treated surface and cured, the discrepancy in hydrophilicity of 
surfaces make them easily separable. Consequently, desired patterned 
PDMS can easily be removed. 
 
 
Figure 2-3. Self-assembled monolayer of PDMS surfaces. a) oxygen 
plasma treatment. b) silanization. 
 
Silanization of PDMS layer is a two-step process. The hydrophobic 
surface of PDMS is composed of methyl groups. By oxygen plasma 
treatment of the surface, the methyl gourds break to form hydroxyl 
groups. Since oxygen plasma treatment, forming hydroxyl groups on the 
surface, is a volatile process, the treated PDMS is placed in a vacuum 
chamber with a drop of trichlorosilane. SAM coatings are normally 
implemented to increase hydrophobicity of PDMS surfaces. This 
hydrophobic modification of PDMS substrates depended on the duration, 
power and oxygen concentration of the oxygen plasma treatment that 
was implemented prior to vacuum deposition. Here, short duration, low 
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power, low oxygen concentration was tested to render PDMS surfaces 
slightly hydrophilic. In doing so, precaution steps are necessary since 
vaporized trichlorosilane releases toxic gas harmful in many ways. 
Moreover, trichlorosilane liquid used in this process is harmful in liquid 
state too. Oxygen plasma treatment is harmless. However, during 
silanization, all procedures must be handled in a fume hood with 
protective gloves and garments.  
 
2.3.4.  Plasma Bonding 
 
 
Figure 2-4. Plasma bonding of two fully cured PDMS.  
 
PDMS to PDMS bonding can be executed through two methods. As 
mentioned above, when liquid PDMS is poured over fully polymerized 
PDMS, the two combine as one. Here, liquid PDMS was used as a 
bonding agent. However, this method can only be applied in a few 
applications. Plasma bonding via oxygen plasma treatment can be used in 
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a variety of fields. Moreover, bonding onto other surfaces such as glass 
can also be implemented. As mentioned above, oxygen plasma treatment 
removes hydrocarbon groups and forms hydroxyl bonds on the surface. 
When two treated PDMS surfaces come in contact with each other, this 
allows strong silicon to oxygen to silicon bonding.  
 
2.4. Fabrication 
In this section, fabrication methods to develop inflatable PDMS 
chambers and alternative methods to achieve PDMS etching results are 
introduced. PVC stencils were prepared using the DPSS Laser system 
and a blade plotter. With the stencils that act as masks, only oxygen 
plasma treatment and silanization were implemented to fabricate the 
structures.  
 
2.4.1. PDMS Etching via PVC Stencils 
PVC stencils were prepared using both a DPSS laser system and a 
blade plotter. Stencils with length 2 cm and widths ranging from 100 m 
to 1 mm were tested to execute PDMS etching. PVC adhesive sheets 
have a thickness of approximately 80 m. For the DPSS laser system 
settings were fixed to 100% laser power, frequency of 20.00 Hz, mark 
speed of 100.00mm/s, and pulse width of 20 s. Even with this laser 
setting, single pass over PVC stencil does not fully cut out the designed 
stencil. Multiple passes were implemented to completely cut out the 
stencils with desired designs. A minimum of 30 passes were require to 
cut the PVC stencils. However, the polyacrylic adhesive side of the PVC 
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sheets were not completely trimmed. Therefore, for the polyacrylic 
adhesive side to be completely trimmed, an additional 20 times and a 
total of 50 passes were executed. The Silhouette blade plotter cut stencils 
with a physical blade. The settings possible with the device is plotting 
speed and blade depth. With the stencils prepared, the stencils’ widths 










The fabrication process starts with preparing a wafer (Figure 2-5a). 
Single side polished wafers with 100 mm diameter, 525 m thickness, 
Boron doped and resistivity of 1-10 Ω.m. If PDMS is spin coated over 
this wafer, PDMS forms irreversible bonds with the wafer surface and 
retrieving PDMS structures is impossible. Therefore, this wafer is 
silanized for easy retrieval. Prior to silanization, to promote strong 
adhesion of vapor deposition, the wafer was treated with oxygen plasma 
treatment at an RF power of 5W, 10.0 sccm (standard cubic centimeter 
per minute), for 60 seconds. Then, this wafer was placed in a vacuum 
chamber with two to three drops of trichlorosilane. The chamber is 
degassed and locked. The wafer is left in the chamber overnight (Figure 
2-5b). This process is very important throughout the proposed fabrication 
process because layers of PDMS structures may not be retrievable. 
Before the next step, a thin layer of PDMS was spin coated over the 
wafer to test if the layer could be peeled off without damaging the 
structures. After silanizing the wafer and tested, PDMS of arbitrary 
thickness is spin coated over the wafer (Figure 2-5c). This layer should 
be at least 100 m thick for later steps to come. The designed stencils 
have to be pasted on this layer. These designed stencils are removed from 
the sheet using a transferable application tape. Even without this 
application tape, simple stencils with thick fragments can be easily 
transferred onto the PDMS surface. However, when the stencils become 
smaller with micrometer scale size fragments, without the application 
tape, the design cannot be sustained during the transferring process. 
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Therefore, a transferable application tape (Silhouette Trans Paper, 
Silhouette, USA) is cut out sufficiently larger than the stencil design. 
This application tape is pasted over the designed and cut out stencil. 
When the application tape is peeled off, the design is peeled off taped on 
the adhesive side of the application tape. This application tape is then 
pasted on the PDMS surface and peeled off. The intension of this process 
is so that the stencil designs are left in on the PDMS surface while only 
the transfer tape is removed. Moreover, weak adhesion of the PVC 
stencil with PDMS surface can cause problems during oxygen plasma 
treatment. Oxygen plasma treatment requires a medium vacuum (25 to 
10-3 Torr) chamber, approximately 7.0~8.0 × 10-2 Torr before oxygen 
injection. With weak adhesion strength between PVC adhesives and 
PDMS surface, PVC stencils can be lifted off the PDMS surface in low 
pressurized chamber. However, the hydrophobic surface of the fully 
polymerized PDMS has low energy. Therefore, the PVC stencil 
adhesives and the PDMS surface form very weak bonds. The application 
tape and the PVC form stronger bonds than PVC adhesives do with the 
PDMS surface. Therefore, an additional process that increase surface 
energy of PDMS is necessary. Oxygen plasma is not adequate for this 
process because the plasma treated PDMS surface and the PVC adhesive 
side form irreversible bonds like PDMS to PDMS bonding. Successive 
steps of this process requires the stencils to be peeled off without 
damaging the underlying substrate. Therefore, silanization is 
implemented using trichlorosilane on this PDMS surface prior to stencil 
transferring (Figure 2-5e). After the stencil is securely pasted on the 
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PDMS surface, liquid PDMS is spin coated over this surface with desired 
thickness. However, to promote strong adhesion of PVC adhesives on 
PDMS substrates, silanization was performed. As mentioned earlier, 
silanization is usually performed to build a barrier between fully 
polymerized PDMS and newly deposited uncured PDMS. When uncured 
PDMS is deposited over this silanized surface, the two detach easily. 
Moreover, PDMS etching is completed with the removal of the stencil 
which too removes PDMS that covers the stencil. Here, with silanization 
still intact, when the stencil is removed from the surface, the whole layer 
peels off. So, to ensure strong bonding between silanized surface and 
newly deposited layer, oxygen plasma treatment is executed with the 
stencils pasted on the first PDMS layer (Figure 2-5f). Oxygen plasma 
treatment is executed at an RF power of 5W, 10 sccm, for 45 seconds. 
After plasma treatment, PDMS is coated over this layer (Figure 2-5g). 
This layer is then cured on a hot plate at 100°C for 15 minutes. After full 
polymerization is achieved, the device is placed in room temperature for 
at least 15 minutes. Cooling down time is necessary because the stencil’s 
adhesive side slightly melts in 100°C. When the stencil is peeled off 
without cooling down, adhesive residue may be left on the PDMS 
surface (Figure 2-5h). This etching process was designed to bear smooth 
surface. Adhesive residue left on the surface may increase surface 
roughness which is not what is expected through this process.   
 
2.4.2.  Inflatable Chamber Fabrication  
Inflatable chamber is too fabricated only using oxygen plasma 
 
 ６０
treatment, silanization and PVC stencils. Stencils and wafers are 
prepared similarly as the previous PDMS etching procedure. Selective 
bonding of PDMS surfaces is implemented to fabricate the inflatable 
chamber. To test the selective bonding process, circular stencils with 
various size ranging from 2 mm to 8 mm in radius were tested. These 
circular stencils all have a concentric circular engraving in the center 
with a radius of 750 m. This small circular stencil is there to make an 
entry point into the detached area.  
With silanized wafer, PDMS is spin coated with desired thickness 
(Figure 2-6a). To test selective bonding, the layer was fixed to 100 m. 
Moreover, if the thickness dropped below 100 m substantially, 
problems may happen in successive steps. PDMS is spin coated over the 
wafer with a series of spin coating recipes: 500 rpm for 5 seconds, 1000 
rpm for 15 second, and 500 rpm for 5 seconds. After curing on a hot plate 
with 100°C for 5 minutes. After full polymerization, this PDMS is 
silanized with the same recipe mentioned above (Figure 2-6b). Similarly, 
the circular stencil is pasted on this PDMS surface and treated with 
oxygen plasma treatment (Figure 2-6c). Different from the previous 
etching method, the larger circular stencil is removed (Figure 2-6d). 
Removing this stencil must be done in a careful manner so that this 
action does not damage the PDMS layer. Slightly lift an edge of the 
stencil using a sharp blade, then with a tweezer, peel off the stencil 
slowly. As mentioned above, the PDMS substrate must be thicker than at 
least 75 m and close to 100 m just to be safe. If the thickness of 
PDMS substrate drops below 75 m, the strong adhesion strength formed 
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between PVC adhesives and silanized PDMS may peel the substrate off 
the wafer or even worse tear the thin PDMS layer. The smaller circle is 
left on the surface (Figure 2-6d). After peeling off the stencil, PDMS is 
spin coated over this layer with a recipe of 500 rpm for 5 seconds, 1500 
rpm for 15 seconds, and 500 rpm for 5 seconds (Figure 2-6e). This 
developed approximately 75 m thick PDMS. Curing on a hot plate for 5 
minutes at 100°C, the wafer is removed and cooled for 15 minutes. 
Similar to the etching process elaborated above, the smaller circular 
stencil is peeled off from the wafer tearing off the new deposited PDMS 
layer (Figure 2-6f). This process bears two PDMS layers only detached 
on surfaces covered by the circular stencil. The second PDMS layer is 
punctured at the center with a size equal to the smaller circular stencil. 
Finally, this inflatable chamber is finished by bonding a thick slab (at 
least 3 mm thick) of PDMS (Figure 2-6g) with a hole with diameter of 
1.75 mm punctured using a biopunch. This hole and the hole in the 
PDMS double layer is aligned and bonded via oxygen plasma treatment 
at RF power of 5W, 10 sccm, for 60 seconds. To test the detachment of 
the membrane, a syringe is connected to the hole. The chamber is inflated 













2.4.3.  Full Fabrication of the Drug Delivery Device 
 
 
Figure 2-7. PVC stencil designs required to fabricate the device 
 
In this section, full fabrication of the proposed drug delivery device 
is elaborated. The fabrication of the device can be divided into three or 
 
 ６４
four parts depending on the actuation mechanism. Four separate wafers 
are required for both magnetic and electromagnetic actuation of the 
device. Primary, secondary chamber and a microchannel that connects 
the primary and secondary chambers are fabricated on one wafer. A 
microvalve that utilize a neodymium magnet is fabricated on another 
wafer. A magnetic membrane that attracts the magnet to ensure closure of 
the microvalve is fabricated on another wafer. For magnetic actuation, a 
thick slab of PDMS (thickness ≈ 1.5 mm) with a cylindrical groove with 
depth of 1 mm and radius ranging from 3 to 5 is prepared on the last 
wafer. Fabrication steps of each component are illustrated and explained 
in depth. PDMS etching and selective bonding processes are used along 
with the PVC stencil designs in Figure 2-7 shows all the PVC stencil 
designs that are required to fabricate the drug delivery device. Figure 2-
7a = secondary pump layer, Figure 2-7b = primary chamber layer, Figure 
2-7c = microchannel layer, Figure 2-7d = microvalve layer_1, and Figure 
2-7e = microvalve layer_2. 
 




Figure 2-8. Fabrication of the chamber layer of the drug delivery device. 
 
Fabrication of the reservoir layer starts with silanizing the wafer. The 
first PVC stencil, rectangular band stencil is pasted on the wafer using an 
application tape. This rectangular band works as an alignment key for 
successive layers that require precise positioning. Silicon wafer is 
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naturally hydrophilic. Therefore, pasting PVC stencils over the wafer 
does not require silanization. However, to easily remove PDMS 
structures from the wafer without damaging them require a silanized 
layer coating over the wafer surface. Over this layer, 3 mL of procured 
PDMS is spin coated with a series of coating recipes: 500 rpm for 5 
seconds, 1500 rpm for 15 seconds, and 500 rpm for 5 seconds (Figure 2-
8a). This first PDMS layer is approximately 75 m thick. After curing on 
a hot plate at 100°C for 15 minutes, the layer is silanized using 
trichlorosilane. Retrieving the wafer from the vacuum chamber after a 
couple of hours, the secondary pump PVC stencil is pasted. This second 
stencil is aligned with the rectangular band and pasted. This second 
stencil is a circular shaped stencil with radius 1.5 mm to 2.0 mm. Two 
smaller circles with radius 375 m are trimmed within this circle. These 
circles are the inlet and outlet of the secondary pump. Using this stencil, 
selective bonding is executed over this first PDMS layer (Figure 2-8b). 
With the stencil pasted on the first layer, the surface is treated with 
oxygen plasma at 5W RF power, with 10 sccm for 60 seconds. After 
plasma treatment, the larger circular stencil is removed. Here, the small 
inlet and outlet stencils are still intact on the surface. Over the PDMS and 
PVC stencil, PDMS is spin coated with consecutive recipe of 500 rpm 
for 5 seconds, 1000 rpm for 15 seconds, and 500 rpm for 5 seconds and 
cured on a hot plate at 100°C for 15 minutes (Figure 2-8c). This surface 
is then silanized again. Retrieving the wafer from the chamber after a 
couple of hours the primary pump stencil is aligned and pasted. This 
stencil is composed of three components: inlet, outlet, inflatable chamber, 
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and inflatable microchannel. After oxygen plasma treatment, the chamber, 
and microchannel portions are removed from the surface while the inlet 
and outlet portions are intact (Figure 2-8d). Then, PDMS is spin coated 
over this surface and cured (Figure 2-8e). Silanization of this surface is 
executed again and the microchannel stencil is pasted on this surface 
aligned with the inlet of the secondary pump and the outlet of the 
primary chamber. Finally, after oxygen plasma treatment, uncured PDMS 
is spin coated over this surface (Figure 2-8f). The chamber layer is 
finished with removing all the remaining stencils from the wafer. 
Removing the stencil removes the PDMS coated over the stencil. Thus, 
this action produces results similar results to PDMS etching.   
 
2.4.3.2. Microvalve 
The microvalve utilized in the drug delivery device is composed of 
two compartments. A thin membrane that can be deflected with the 
presence of a magnetic field, and a magnetic PDMS composite 
embedded PDMS slab that tightly encloses the deflectable membrane 
compose the microvalve used in the device. A neodymium permanent 
magnet is bonded on to the deflectable membrane on the opposite side of 












Figure 2-10. Plasma bonding of the two compartments that compose the 




Fabrication of the microvalve layer again starts with two silanized 
wafer. Each compartment of the device is developed on a separate wafer. 
First, fabrication of the magnetic slab is elaborated. Over a silanized 
wafer, a thin layer of approximately 95 m PDMS was spin coated. This 
PDMS surface is then silanized with the same recipe introduced above. 
PVC stencil (Figure 2-7d) is pasted over this surface and the larger 
circular band stencil is peeled off (Figure 2-9a). This surface is then 
treated with oxygen plasma at 5W of RF power, 10 sccm, for 60 seconds 
(Figure 2-9b). The empty void of the PVC pattern is now filled with 
PDMS and nickel composite. PDMS and nickel composite was mixed 
with a weight ratio of 5:3.5. The composite prepared earlier is poured 
over the stencil. With a sharp blade, excess volume of the composite is 
removed by scraping off the surface. As the composition of nickel 
particles increase, this scraping motion can lead to inconsistent formation 
within the membrane. To avoid this inconsistency, a strong permanent 
magnet is placed right beneath the wafer aligned with the stencil to hold 
magnetic particles in place (Figure 2-9c). After curing, the remaining 
PVC stencils are removed from the wafer (Figure 2-9d) and PDMS is 
poured over to develop a PDMS slab with approximately 500 m thick 
profile. A hole with 1 mm diameter is drilled through the center of the 
circular composite (Figure 2-9e). The second part of the microvalve is 
the deflection membrane with inlet and outlet. Similarly, a layer of 
PDMS is spin coated over the silanized wafer with a recipe of 500 rpm 
for 28 seconds. Curing at 100 °C for 15 minutes, the surface is silanized. 
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PVC stencil (Figure 2-7e) is pasted over this surface (Figure 2-9f). This 
stencil is composed of three parts. A circular patch that accounts for 
deflection membrane, circular inlet and a channel shaped outlet. This 
surface is treated with oxygen plasma with the stencil intact. Then, only 
the large circular stencil is removed and another layer of PDMS is spin 
coated over with the same recipe (Figure 2-9h). After curing, the 
remaining stencils are removed (Figure 2-9i). Fabrication of the 
microvalve is completed by plasma bonding the two compartments 
aligning them with the inlets of each compartment. Figure 2-9 shows the 
two compartments of the microvalve. The two are aligned with the inlets 
and bonded through oxygen plasma treatment. The cross-sectional view 
of the valve in Figure 2-10 show the working mechanism of the valve.  
 
2.4.3.3. Magnetic Actuation Component   
This last component of the device differs whether the device is 
actuated with a permanent magnet wirelessly or electromagnetically with 
a power source connected. For a magnetically actuated device a rather 
thick slab of PDMS approximately 1.5 mm in thickness with a 
cylindrical furrow with radius equal to the size of the deflection 
membrane and depth of 1 mm. This slab of PDMS is plasma bonded over 
the deflection membrane completely encapsulating the deflection 
membrane and the permanent magnet. This is necessary to enforce 
stronger closure of the valve. As the pressure in the primary and 
secondary pump increase and exceeds the valve’s threshold, there is a 
chance the valve will open and leakage of drug substances out of the 
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device can ensue. Bonding the slab over the valve produces a cylindrical 
void encapsulated with PDMS all around. This air tight capsule promotes 
higher pressure over the deflective membrane that consequently require 
the valve a higher actuation force to open. 
Fabrication of the flexible conductive coil starts with a silanzied 
wafer. This wafer is then coated with PDMS with approximately 150 m. 
This can be achieved by dispensing 3 mL of pre-cured liquid PDMS 
mixture over the wafer and spinning with a recipe of 500 rpm for 30 
seconds (Figure 2-11a). PDMS is cured and silanized. Positive PVC 
stencil of the coil is pasted on this surface and treated with oxygen 
plasma (Figure 2-11b). Then, PDMS is spin coated over this stencil to 
have thickness of approximately 250 m (Figure 2-11c). After curing, 
this PDMS surface silanized. Over this surface, negative PVC stencil of 
the stencil is aligned with the positive stencil and pasted (Figure 2-11d). 
Then, the positive stencil is peeled off bearing etching results on the 
surface. The groove produced in this procedure is approximately 330 m 
deep. Over this surface, silver micropowder and PDMS is mixed in a 
ratio of 5 to 1. The mixture produces a composite too lumpy to execute 
screen printing. Screen printing is a procedure used when magnetic 
PDMS patterning was implemented in previous procedures. The 
composite is dispensed over the surface. However, the lumpy composite 
cannot be injected into the microgrooves by scraping off the composite 
using a sharp blade. Therefore, highly volatile solvent was mixed in a 1 
to 1 volume ratio with the composite to temporarily develop a slurry 
mixture. 80% ethanol mixed with 20% DI water was used here. Highly 
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volatile solvents such as n-Hexane can also do the job. However, PDMS 
swells up when it comes in direct contact with highly volatile substances 
[134]. Now the mixture is slurry enough to be screen printed (Figure 2-
11f). Finally, the negative PVC stencil is removed from the layer and the 
PDMS surface is treated with oxygen plasma treatment. An 
encapsulation layer is dispensed over the surface completing the 





















3.1. PVC Stencil Preparation 
 
 
Figure 3-1. DPSS laser and blade plotter preciseness comparison. 
Figure 3-1 is a chart analyzing both stencil preparation devices. Each 
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device was programmed to cut out stencils with width ranging from 1 
mm to 100 m. The widths of stencils cut out using each devices were 
measured using a Scanning Electron Microscope (SEM). Figure 3-1 a 
and b shows cutting profile of a DPSS laser and a blade plotter. DPSS 
laser system uses a high power laser that burns through the PVC material 
while blade plotters cut through with a physical blade. Figure 3-1a 
manifests the burned surface of PVC. The burning width can be 
controlled by the number of passes over the stencil. However, a certain 
amount of passes are required to burn through the 80 m thick PVC 
sheet. At least 30 passes are required to burn through the PVC and the 
polyacrylic adhesives. 30 passes may be enough to cut through the PVC 
sheet. However, it may not be enough to clearly cut through the 
polyacrylic adhesives. At least 50 passes are required to cut through the 
polyacrylic adhesives. When 50 passes are burned through the PVC sheet, 
the width is approximately 20 m. Therefore, thickness error of the 
DPSS laser device does not only arise from the device itself but also 
from the burning nature of the laser. Figure 3-1b manifests a groove 
made by the blade that passed over through the PVC sheet. Blade plotters 
do not burn through the PVC. Thus, thickness error produced by blade 
plotters arise from the devices’ mechanism only.  
Chart in Figure 3-1 shows the thickness preciseness of both devices. 
DPSS laser analysis is depicted in blue (x) and blade plotter is depicted 
in red (o). Stencil preparation was repeated 20 times for analysis. DPSS 
laser’s analysis shows that the results are slightly smaller than desired 
and designed size. However, deviations from the average value was very 
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small. Blade plotters, however, use two motors that control the vertical 
and horizontal movement of the blade. These motors are not precise 
enough to cut down to a few hundred micrometer size fragments. The 
chart shows an average value slightly larger than desired and designed 
size. Moreover, the deviation of cut out stencils were too large. Therefore, 
the results were not reliable. Upcoming experiments and procedures were 
all implemented using PVC stencil acquired using only DPSS laser 
system.  
 
3.2. Surface Modification and Selective Bonding 
 
Fabrication of the inflatable chamber begins with surface 
modification and selective bonding using this surface modification 
method. PDMS surface modification is critical to the PVC fabrication 
methods proposed in this paper: increased surface energy to enable 
secure fixation and transfer of PVC stencils onto innately hydrophobic 







Figure 3-2. Surface modified PDMS surface using PVC stencils.  
 
Figure 3-2 is an image of PDMS surface treated with oxygen plasma 
treatment and silanization to render the surface hydrophilic. A concentric 
design of PVC stencil was pasted on a silanized PDMS surface. This then 
was treated with oxygen plasma at an RF power of 5W, with oxygen 
concentration of 5 sccm for 30 seconds. The stencil was removed and the 
surface was place in a freezer for a minute. When it is retrieved from the 
freezer, the rapid change in temperature from below zero to room 
temperature, allows thin layer of frost to form on the surface. This only 
happens on hydrophilic surfaces. The image in Figure 3-2 shows the 
degree of hydrophilicity of the treated PDMS surface depending on 
whether it was treated only with oxygen plasma or silanized. Oxygen 
plasma treatment gives surfaces with higher hydrophilicity than silanized 





Figure 3-3. Water drop test on hydrophilic altered PDMS surfaces with 
varying oxygen plasma treatment duration. 
 
Figure 3-3 are images of water drop test on bare, oxygen plasma 
treated, three different durations of oxygen plasma treated, and silanized 
then oxygen plasma treated PDMS surfaces. Oxygen plasma treatment 
was implemented with three different RF power states, 5W, 50W, and 
150W. The duration of oxygen plasma treatment was varied from 30 
seconds, 2 minutes, and 5 minutes. Here, the oxygen flow rate was fixed 
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to 10 sccm. Water drop test was executed to investigate how the surface 
properties of PDMS was modified. Water drop angle was measured for 
each oxygen plasma duration to show how much the surface was 
modified. Bare PDMS surface has a water contact angle of 
approximately 99 degrees (Figure 3-3a). Oxygen plasma treated surfaces 
have a contact angle of less than 10 degrees (Figure 3-3b). As many 
experimental results show, the oxygen plasma treatment implemented 
prior to vapor coating trichloro (1H, 1H, 2H, 2H-tridecafluoro-n-octyl) 
silane gives variance in how much the PDMS surface is modified. The 
silanized PDMS surfaces manifest change in surface energy as the 
oxygen plasma treatment duration increases, or the plasma treatment RF 
power increases. From 99 degrees of bare PDMS water contact angle, as 
the duration of oxygen plasma treatment increased, the water contact 
angle first begins to degrease down to 44.25 degrees. As the RF power 
increases, the contact angle increased up to 77.88 degree. Here, the 
plasma treatment duration was fixed to 2 minutes. Under same conditions 
in power and oxygen flow rate, when duration was increased to 5 
minutes, PDMS surface was modified slightly more hydrophobic. The 
contact angles were increased up to 110 degrees. As the duration of 
plasma treatment increases, PDMS surfaces display hydrophobic return. 
Figure 3-4 shows two charts that depict the change in water contact 
angle on different PDMS surfaces. Figure 3-4a is a chart with 4 types of 
PDMS surfaces: three types of treated and one untreated PDMS. Treated 
PDMS surfaces were treated with oxygen plasma with a flow rate of 10 
sccm for two minutes. The difference in each surfaces was the RF power 
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of the process was 5W, 50W, and 150W. Figure 3-4b, similarly, depicts 4 
different types of surface modified PDMS. The difference between 
Figure 3-4a is the oxygen plasma treatment duration. The process time 
was increased to 5 minutes. Longer processing time shows the increase 
in contact angle.  
 
 
Figure 3-4. Surface modified PDMS via silanization with variance in 
oxygen plasma treatment.  
 
Higher power and longer duration of oxygen plasma treatment was 
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not implemented because the process does not only render the surface 
hydrophilic, but also produces small and large cracks on the surface. The 
high temperature induced by the plasma treatment for longer duration 
and higher power can increase the degree of crack produced on the 
treated surface. The problem to this crack surface is that it does not only 
modify the surface properties, but also the tensile strength of the film 
itself.  
The surface modification is crucial in this procedure in that the 
patterned PVC stencils can be securely fixated on the surface using the 
transfer paper. Figure 3-5 shows the difference in surface modification of 
PDMS when transferring PVC stencils using the transfer paper. Figure 3-
5b shows that the stencil cannot be transferred onto the PDMS surface 
because of its low surface energy. When the transfer film is peeled off, 
the stencil design is still intact on the film rather than on the PDMS 
surface. On the other hand, Figure 3-5c shows successful transfer of PVC 
stencils onto the PDMS surface due to increased PDMS surface energy. 
Figure 3-5d are examples of more complex designs that could be 
successfully transferred onto the treated PDMS surface. 
Selective bonding of PDMS surfaces is shown in Figure 3-6. A 
circular stencil with a microchannel stencil connected to an inlet stencil 
was used to test the surface modification. Figure 3-6a is the surface 
treated PDMS with the stencil peeled off. The stencil boundary can be 
visualized due to the difference in surface properties after oxygen plasma 





Figure 3-5 Transferring PVC stencils onto PDMS surfaces. 
 
On the surface in Figure 3-6a, PDMS is spin-coated and cured. The 
surface covered by the stencil, thus not treated with oxygen plasma 
treatment, is detached while the other surface, treated with oxygen 
plasma treatment, is strongly bonded. Figures 3-6 c and d show images 
of selectively bonded PDMS double layer. A thick slab (≈5 mm) of 
PDMS is pasted on the selectively bonded PDMS. This slab has a hole 
punctured to connect a syringe tube to inject fluid into the detached area. 
A tube is injected into the hole and through a syringe, red-dyed DI water 
was injected. The thin membrane inflates verifying the detached and 





Figure 3-6. Selective bonding of PDMS surfaces. Selective bonding 
testing by injecting red-dyed DI water and inflating the chamber. 
 





Figure 3-7. Polymerization inhibition of PDMS over PVC substrates. 
 
PDMS polymerization inhibition over PVC substrates is investigated. 
Figure 3-7 are images that illustrate the degree of PDMS polymerization 
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inhibition over PVC substrates with respect to the thickness of PDMS 
dispensed over the substrate. Figures 3-7 a, b, c show full inhibition of 
polymerization, Figures 3-7 d, e, f show partial polymerization and 
Figures 3-7 g, h, i show full polymerization over PVC substrates. A 
rectangular stencil with 1 cm by 1 cm was pasted over a silanized wafer. 
Precured liquid PDMS was dispensed over the wafer and spin coated 
with 10 different recipes ranging from 500 rpm to 5000 rpm for 15 
seconds with 500 rpm interval. Each recipe started and ended with 500 
rpm spinning for 5 seconds each for leveling procedures.  
The degree of polymerization inhibition of PDMS over PVC stencils 
with respect to the thickness was experimentally obtained. The chart in 
Figure 3-8 shows the relationship between spin-coating recipes and 
PDMS thickness formed on the PVC stencil. Total inhibition of PDMS 
was observed when the thickness was less than 20 m, colored area in 
blue. When the thickness was in between 80 and 20 m, partial 
polymerization was observed, colored area in green. Lastly, when the 
thickness was greater than approximately 100 m, inhibition was negated 





Figure 3-8. The degree of polymerization inhibition with respect to the 
thickness of PDMS dispensed on the PVC substrate. 
 
3.4. PDMS Etching  
 
The conventional PDMS etching method utilize etching solutions 
and fluorine based RIE integrated with photolithography patterning. 
However, these methods either produce etched PDMS surface with 
substantial surface roughness or lateral etching that cannot be controlled 
with high precision. The proposed method that utilize PVC stencils and 
PDMS polymerization inhibition can be used to implement fast and 
simple fabrication that can produce etched surfaces.  
Depending on the thickness of PDMS dispensed on the stencil, 
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which equals the thickness of the desired etched depth, the degree of 
inhibition of PDMS polymerization can be obtained. PDMS etching was 
executable even when PDMS fully polymerized. However, the etching 
cross-sectional profile differed and depended on the degree of 
polymerization inhibition. PDMS inhibition occurred only on PDMS 
directly in contact with the PVC stencil. When PDMS is spin-coated on 
the pattern pasted surface, both PVC stencil and oxygen plasma treated 
PDMS surface are coated with fairly equal thickness. After curing, 
PDMS on the stencil either fully polymerize, partially polymerize, or 
does not polymerize at all. In cases where polymerization is inhibited, the 
fully polymerized PDMS on PDMS substrates and the polymerization 
inhibited PDMS on the PVC stencil form a weak bond directly on top of 
the stencil boundary. Due to this weak bond that formed directly on top 
of the boundary, the simple peel off action of the stencil tears the 
polymerization inhibited PDMS on the weakly bonded boundary. 
Therefore, when PDMS is spin-coated thin enough for inhibition to occur, 
the etched surface produces a vertical profile cross-sectional shape. 





Figure 3-9. SEM images of microchannels’ cross-sectional profile. The 
channels show vertical profile shapes.  
 
Even in cases where PDMS polymerization inhibition is not present, 
PDMS etching is possible. The weak bond that is present in 
polymerization inhibited PDMS does not exist here in this condition. 
Therefore, the same peel off action can develop PDMS etching results. 
When PDMS is spin-coated thick enough for PDMS polymerization to 
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fully happen, the PVC stencil is completely encapsulated by fully 
polymerized PDMS. The first and second PDMS layers spin-coated 
separately, are bonded irreversibly by oxygen plasma treatment. The 
same peel off action of the PVC stencil can develop PDMS microgroove 
for a number of reasons. PDMS is a flexible material with relatively low 
fracture strength. Moreover, the tensile strength of PDMS is proportional 
to the thickness. When the PVC stencil is peeled off, the second PDMS 
layer tears off on the thinnest position. However, the peel off action does 
not produce a vertical profile channel. The tearing of PDMS produces 
channels with overcut profile. Figure 3-10 shows a diagram of overcut 
profile PDMS channels produced using the proposed method.   
 
 
Figure 3-10. Diagram of the overcut profile produced by the proposed 









Figure 3-11. SEM images of microchannels’ cross-sectional profile. The 
channels show overcut profile.   
The absence of inhibition requires the peel off motion to tear PDMS 
on the thinnest boundary. The tearing forms a certain angle. This angle, 
pointed out in Figure 3-10, is proportionate to the stencil width and the 
thickness of the second PDMS layer. The relationship between the angle, 
opening width, stencil width, and second PDMS layer is analyzed and the 




Table 3-1. Cross-sectional profile of patterned PDMS microchannels 
 
 
To analyze the tearing angle of the cross-sectional profile, multiple 
thicknesses of second PDMS layer were tested. When the second PDMS 
layer was thinner than 75 m, thus polymerization inhibition was present, 
the cutting angle was 0 degrees. The error in these results were too small 
and thus had no critical effect. As the thickness increase with thicker 
second PDMS layer, polymerization inhibition was not present and the 
cross-sectional shape of the microchannels showed an overcut profile. 
Analysis in Table 3-1 shows that the cutting angle was proportional to the 
thickness of the second PDMS layer and inversely proportional to the 
width of the stencil.  
 





Figure 3-12. Three dimensional microchannel fabrication method. 
 
With the PVC fabrication method, simple and fast fabrication of 
multilayer microchannel is feasible. Three dimensional microchannel 
devices are advantageous over the conventional two dimensional in 
improved observation efficiency, continuous three dimensional motion 
and integration of more functions. The simplest three dimensional 
microchannel fabrication method utilize the conventional two 
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dimensional fabrication method. Photolithography patterning is executed 
multiple times and bonded via oxygen plasma treatment. This oxygen 
plasma treatment is a permanent procedure. The essence of bonding to 
manufacture three dimensional microchannels is the alignment of the 
connecting junctions in multiple levels. However, plasma bonding is an 
irreversible procedure where misalignment of the bonding site results in 
complete failure that requires the procedure to start from step one.  
The PVC stencil method can be repeated multiple times. Moreover, 
the fabrication method is reversible during the critical alignment process. 
Repeating the PDMS etching procedure with only a few specifications 
can easily produce PDMS three dimensional microchannels. When the 
PVC stencil is peeled off, the junction portion of the stencil is still intact. 
Then, this patterned surface in bonded onto a thin PDMS surface. Now, 
the second PVC stencil is pasted on top of this layer aligned with the first 
layer’s junction portion of the stencil. Third PDMS layer is dispensed on 
this layer and stencil.  This procedure can be repeated as many times as 
desired. Thus, developing layers of patterned PDMS microchannels 
aligning, and integrating can be realized rather easily. Figure 3-13 shows 
three dimensional PDMS microchannels with two layers. Figure 3-13a is 
an image of two layers of disconnected PDMS microchannels and Figure 
3-13b is an image of two layer of PDMS microchannels connected 
through a junction. The channels are 150 m wide and 250 m deep. 
Figures 3-13c and d is a magnified image of the two layers of PDMS 





Figure 3-13. Three dimensional microchannels developed using the PVC 
fabrication method. 
 
3.6. Circular Cross-sectional Microchannel 
The selective bonding of PDMS surfaces allow easy fabrication of 
circular cross-sectional microchannels. The PVC stencil’s width 
determines the diameter of the circular channels. The fabrication process 
is identical to the chamber fabrication procedure. The stencils are 
changed to have widths with desired diameter of the channels. Most 
importantly, only an inlet is required. After selective bonding is 
implemented, the channel is inflated by injecting olive oil. The 
substances injected into the channels should be carefully considered 
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because some substances can diffuse across the PDMS membrane. 
Substances such as water should not be selected because water will 
diffuse across the membrane and subsequently, the internal pressure of 
the channels will decrease. The circular shape of the channels cannot be 
controlled. Inflated, the inlet is sealed. Then this is then immersed in a 
PDMS bath and cured. After curing, the cross-sectional images were 
analyzed to verify the circular shape of the channels.  
 
 
Figure 3-14. Channel inflated by injecting olive oil into the channels with 
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widths measuring approximately 500 m. 
Figure 3-14 show the inflated microchannels developed using a 
bifurcated PVC stencil. In Figure 3-14a the channel starts to inflate as the 
channels are injected with olive oil. Figure 3-15 are SEM images of the 
cross-sectional images of the circular microchannel. The channel’s cross-
sectional shape can be controlled by the internal pressure of the channels.  
 
 




3.7. Inflatable Chamber Fabrication 
 
Circular inflatable chambers are fabricated using the method 
introduced in Figure 2-5. The stencils were designed to have an inlet, a 
circular shaped inflatable chamber, and a thin inflatable microchannel. A 
Teflon tube connected to a syringe is inserted into the inlet. As the 
syringe is pushed and DI water is injected, the microchannel inflates first. 
Substances travel into the chamber through the microchannel 
subsequently inflating the chamber. As the chamber inflates, the internal 
pressure continues to increase. Then, the tubing is released. There is no 
other mechanism that encloses the inlet than the design itself. The 
substances are bolted by the thin inflatable microchannel that connects 
the inlet to the chamber. Henceforth, called the bolting microchannel. 
The inflatable chamber, bolting microchannel and the inlet are all 





Figure 3-16. Inflated chamber, inlet, and bolting microchannel illustrated 
by injecting red-dyed DI water into the chamber.  
 
In most cases, the inflated chamber does not produce enough power 
to inflate the microchannel. However, if the chamber contains too much 
substance, the inflated membrane can produce enough power to push 
substances out by inflating the bolting microchannel. Therefore, the 
maximum tolerable volume of the chamber was measured after the 
leakage of substances out of the chamber through the inlet completely 
stopped. In this section, the maximum volume tolerable by the chamber 
was investigated in relation to the chamber’s radius, chamber’s 
membrane thickness, and the bolting microchannel’s width and thickness. 
Here, the chamber and the bolting microchannel’s membranes have the 
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same thickness. Circular stencils with 4 to 8 mm radiuses were used to 
test the maximum tolerable volume. 
 
 
Figure 3-17. Maximum tolerable volume of the circular chamber with 
respect to the radius of the chamber and the width of the bolting 
microchannel. 
 
3.8. Conductive PDMS Fabrication 
 
Conductive PDMS fabrication is necessary for the electromagnetic 
actuation to be feasible. However, conductive coil on flexible materials 
such as PDMS are lacks durability. Therefore, a mixture of PDMS and 
silver micro particles were used. Here, a PDMS to silver microparticles 
in weight ratio of 1:2, 1:3, 1:4, 1:5 were tested to analyze the resistance 
and the conductivity this PDMS silver composite can produce. With this 
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composite, a circular shape coil that can produce electromagnetic fields 
were used to actuate the valve. 
 
Table 3-2. Conductivity and resistivity of metals. 
Metal Conductivity (S/m) at 20°C Resistivity (Ω.m) at 20°C 
Silver 6.30 × 107 1.59 × 10-8 
Copper 5.96 × 107 1.68 × 10-8 
Gold 4.10 × 107 2.44 × 10-8 
Aluminum 3.77 × 107 2.65 × 10-8 
Nickel 1.43 × 107 6.99 × 10-8 
Iron 1.00 × 107 9.7 × 10-8 
 
Silver microparticles were used for the fabrication of flexible 
conductive lines that produce magnetic fields to actuated the valve for 
their high conductivity. Table 3-2 shows metals and their corresponding 
conductivity and resistivity. Silver has a conductivity of 6.30 × 107. The 
conductive lines that produce magnetic field lines need to have 
resistances as low as possible to minimize power consumption. Moreover, 
the metal particles have to be mixed with PDMS, an insulating polymer 
with a very low conductivity of 2.50 × 10-14. Therefore, silver 
microparticles are most adequate for the application. Silver, like many 
other metal particles, is toxic to the human body. Since PDMS is 
biocompatible with only mild inflammation while implanted in the body 
and more importantly, the conductive coil is only used to produce 





Figure 3-18. Silver microparticles mixed with PDMS with a weight ratio 
of a) 2:1, b) 3:1, c) 4:1, d) 5:1 
 
Silver microparticles were mixed with PDMS with a weight ratio of 
1:2, 1:3, 1:4, and 1:5. Figure 3-18 shows the results of these mixtures 
with different ratios. For mixtures with 1:2 and 1:3 ratios, the mixture 
sustains a rather viscous fluid state where patterning conductive lines via 
microgrooves is still possible. However, the mixture with less silver 
microparticles have low conductivity and mixing reliability. As the silver 
microparticles increase in ratio to 1:4 and 1:5, the mixture becomes more 
and more slurry. To the point, the mixture becomes too lumpy and cannot 
be used in the patterning process. So, the mixture was mixed with 99.8% 
ethanol sufficiently to increase the viscosity of the mixture. The mixture 
was left for the ethanol to evaporate in case it was mixed too much. This 
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mixture then can be used for the patterning process. For mixtures with 
higher silver concentration than 1:5, PDMS merely act as a glue that 
holds the particles together. Therefore, the mixture has high conductivity 
and the mixing reliability is relatively high, too. To test the conductivity 
of the mixture, PVC stencils with 1.5 cm in length and 1 mm in width 
were used to develop PDMS microchannels with equal dimensions and 
150 m deep. 15 to 20 samples were prepared and the average and 
deviation results were also calculated to show the reliability of its usage. 
Figure 3-19 shows the a) resistance of each strip of silver-PDMS and b) 
conductivity calculated from the resistance and the dimensions of the 
conductive PDMS.  
 
Figure 3-19. a) Resistance of the silver-PDMS conductive lines. b) 





Figure 3-20. Conductive and flexible PDMS fabricated using the 














3.9.1. Dimensions and Profile of the Drug Delivery 
Device 
The proposed drug delivery device has a surface area of 3.0 cm by 
1.5cm. The overall thickness of the device varied depending on their 
primary and secondary pump’s thickness. The device’s overall thickness 
had to be Three different combinations of primary and secondary pump’s 
membrane thicknesses were tested to find the amount of fluid delivered 
each time the device was actuated. DI water was chosen to find the 
released amount at each actuation. DI water was chosen because the 
main purpose of this drug delivery device was to deliver corticosteroids 
such as dexamethasone, triamcinolone, prednisolone etc. The actuation 
was executed using an external magnet. Each actuation lasted for one 
second.  
 
3.9.2. Fluid Release Amount of the Device 
3.9.2.1. Case 1 
Table 3-3. Device Dimensions Case 1 
 Dimensions 








Microchannel Length   1 cm 
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Cross-Sectional Area 100 m by 95 m 
Bolting Microchannel 750 m 
Initial Volume 220 L 
 
 
Figure 3-22. DI water delivery at each actuation. 
 
3.9.2.2. Case 2 
Table 3-4. Device Dimensions Case 2. 
 Dimensions 








Microchannel Length   1 cm 
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Cross-Sectional Area 100 m by 95 m 
Bolting Microchannel 750 m 
Initial Volume 220 L 
 
 
Figure 3-23. DI water delivery at each actuation. 
 
3.9.2.3. Case 3 
Table 3-5. Device Dimensions Case 3. 
 Dimensions 








Microchannel Length   
Cross-Sectional Area 
1 cm 
100 m by 95 m 
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Bolting Microchannel 750 m 
Initial Volume 270 L 
 
 
Figure 3-24. DI water delivery at each actuation. 
Three cases in section 3.9.2 shows the DI water released amount 
from the device with different combination of primary and secondary 
chamber dimensions. Each case was repeated 10 to 15 times where the 





Figure 3-25. Volume change over time when the device only one 
chamber. 
 
Figure 3-25. shows the volume change of a device with only one 
chamber over time. Three different dimensions were tested. The chamber 
had a radius of 7 mm and a bolting microchannel of 750 m. The 
thickness of the chambers were 250 m, 325 m, and 545 m. Each 
chamber was injected with approximately 150 L of DI water. Similar to 
many other drug delivery devices, the chamber rapidly pumps out fluids 
when it is relatively full. As the chamber loses its volume and the internal 
pressure of the chamber decrease, the chamber quickly saturates reaching 
zero dispense rate.  
Three cases in section 3.9.2 show a relatively controlled dispense 
amount with equal actuation. It is apparent that the decrease in delivery 
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amount is inevitable. The released amount of the first and third case 
reduced to approximately half of the first amount after 10 and 15 
actuations. In case of the second, the released amount reached 
approximately one third after 15 actuations. Since the device is an active 
control delivery device, this discrepancy can be easily solved by 
decreasing the release interval   
 
3.10. In Vitro Cytotoxicity of the Device 
 
This proposed drug delivery device uses PDMS mainly. However, 
the use of metal particles such as nickel and silver and the use of 
neodymium magnet raises questions whether the device is in fact 
biocompatible when implanted in the body. So, the fabricated device was 
tested for cytotoxicity with the “ISO 10933-5:2009(E), Part 5: Tests for 
in vitro cytotoxicity –Annex C: MTT cytotoxicity test” standards. Prior 
to elution the device was placed in a solution of 70% ethanol and 
sonicated to wash off dust and other residue. The test was evaluated both 
qualitatively and quantitatively. Elution was executed using 20 mL of 
Minimum Essential Medium (MEM) (GIBCO BRL, Cat. No. 11095-080, 
Lot No. 1858767) solution per 4g of the device. The device was placed in 
the solution for 24 hours in 37 °C. NCTC clone 929 (L-929) (Korean 
Cell Line Bank) cell line was used to evaluate the cytotoxicity. The L-
929 is the connective tissue from 100 days old male mouse; Mus 
musculus (C3H/An). This specific cell line was selected because of its 
sensitivity towards chemical compounds. Moreover, this cell line had 
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been used extensively in many cytotoxicity experiments. Thus, 
comparison between the results can be easily realized.  
The extract from the elution process was used on the cell line for 24 
to 48 hours. The qualitative evaluation was obtained by how much the 
extract hindered the growth of the cells. The qualitative evaluation of the 
devices showed a cytotoxicity score of ‘0’. A cytotoxicity score of 0 
proves that the device has no reactivity on the tested cell line. 
Microtitration test was used to evaluated the device quantitatively. The 
quantitative evaluation also showed no cytotoxic elements in the device.  
 
Table 3-6. Qualitative cytotoxic evaluation of the drug delivery device 
Group Time Test Item
Concentration 










24, 48 MEM 100% Extracts 0 0 
Negative 
Control 
24, 48 HDPE 100% Extracts 0 0 




100% Extracts 0 0 
75% Extracts 0 0 
50% Extracts 0 0 
25% Extracts 0 0 






100% Extracts 4 4 
50% Extracts 3 3 
 
Table 3-6 shows the qualitative evaluation of the drug delivery 
device. MEM, High Density Polyethylene (HDPE) for negative control, 
and 0.25% zinc dibuthyldithiocarbamate (ZDBC) for positive control 
were also tested at the same time to ensure the evaluation process is valid. 
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Negative control showed a cytotoxicity score of 0 while positive control 
showed 3 to 4. The extracts from the drug delivery device were diluted 
from 100% to 75%, 50%, 25%, and 12.5% consecutively. All diluted 
extract and the original extract showed a cytotoxicity score of 0. This 
proves that the device displays no toxic effects.  
Table 3-7 shows the quantitative evaluation of the drug delivery 
device. The process was executed similarly to the qualitative evaluation. 
Similarly, negative control showed a 75.67% of survival rate while 
positive control showed 11.97% and 32.50% for 100% and 50% extracts. 
This value validates the results of the drug delivery device’s extracts. 
Original extract and all four diluted extracts, 75%, 50%, 25%, 12.5% 
showed a high cell survival rate of 95.40%, 96.46%, 101.60%, 100.17%, 
and 103.67% correspondingly. This proves qualitatively that the device is 
nontoxic.  
 




































































Figure 3-26. Cell Viability of L-929 fibroblasts according to the 
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4. Discussion and Future Work 
4.1. Electromagnetic Actuation of the Device 
Electromagnetic actuation of the drug delivery device begins with 
calculating the magnetic field induced by the coil that deflects the valve 
membrane consequently opening the valve. From Biot-Savart Law, the 
equation of the magnetic field produced by the circular conductive coil 













Due to the symmetry of the current produced by the coil, the y 
component of B is negated. Thus, only x component of the field is 






















































Figure 4-1. Schematic of electromagnetic actuation. 
 
Figure 4-1 show the schematic of the electromagnetic actuation. For 
visualization purposes, the deflecting membrane is separated from the 
coil. However, the real device has the two bonded together.  
The drawback of this electromagnetic coil and electromagnetic 
actuation of the device is its durability. To achieve full flexibility, the 
conductive coil was developed only with PDMS and silver microparticles. 
1:4 mixing ratio was selected to be the adequate composition for the 
electromagnetic coil. However, the conductive coil has very weak 
durability. The conductive coil had 2 to 4 Ω resistance depending on the 
thickness and width and size of the designed coil. In this case, even 2 to 4 
V of voltage applied to this coil will produce current with 1 to 2 Amperes. 
As the current flows over 1.5A, the coil starts to burn and the coil’s 
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resistance increase. Consequently, more voltage is required to drive the 
coil’s electromagnetic actuation.  
 
4.2. Drug Delivery Content  
 
The drug delivery device was designed to release corticosteroid 
drugs, such as dexamethasone, triamcinolone, and prednisolone. 
Corticosteroids are used to treat many diseases such as allergic disorder, 
blood disease, certain cancers, eye diseases, dermatologic disease, 
breathing problems etc. However, to treat these diseases, corticosteroids 
are injected through a syringe or by oral gavage. These administration 
methods treat the disease systemically where long-term side effects are 
inevitable. Some of the long-term side effects are decreased bone density, 
gastrointestinal bleeding, increased risk of heart disease, thin skin, bruise 
easily, and slower healing of wounds etc. When these drugs are 
administered using intravenous methods, 2~8 mg of corticosteroid drugs 
are necessary every 3 to 6 hours for the concentration to be in the 
therapeutic range. However, when they are administered locally to 
specific parts of the body for direct release, only 0.05~0.1 mg every two 
weeks for percutaneous, 0.8 ~ 5mg every 2 weeks for articular, and 
0.8~2.5mg every two weeks for tendon are needed. Fortunately, these 
drugs are soluble either in, ethanol, dimethyl sulfoxide (DMSO), or water. 
The reason to why the release amount was tested by DI water is because 
of these characteristics. DMSO is still in debate on whether the solvent 
can hard specific parts of the body. The drug content in grams can be 




4.3. Comparison with Similar Drug Delivery Devices 
 
Figure 4-2. Comparison with other magnetically actuated drug delivery 
devices. 
 
Figure 4-2 are comparison of three devices with similar actuation 
mechanisms. All three devices utilize an external magnetic field using a 
permanent magnet. The fabricated devices use PDMS as their main 
material and utilize mixture of magnetic particles either as an actuation 
membrane or a valve component. However, the mechanisms of the 
devices are rather different. Pirmoradi et al. [115] and W.J. Struss et al. 
[116] use the magnetic membrane to squeeze the drug reservoir filled 
with drug substances whereas the proposed device in this thesis uses the 
magnetic actuation to open the tightly sealed valve. The two previous 
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devices’ actuation deflects a magnetically excitable membrane to push 
out substances. However, the proposed device merely relieves the 
pressure contained by the inflated chamber. It is inevitable that all the 
devices’ drug release amounts will decrease as the actuation numbers 
increase consequently emptying the chamber. However, the two previous 
devices would require stronger actuation mechanism as the drug 
reservoir empties.  
The proposed drug delivery device could handle 250 L of liquid 
substances without leakage happening through either the inlet or the 
outlet of the device. Moreover, the device can be reused by simply 
injecting the chamber with more substances using a syringe.  
Figure 4-3 is a comparison of the proposed device with other relatively 
recently developed active control drug delivery devices. All three devices 
have different actuation mechanisms: magnetic, electrolysis, and thermal. 
The devices share a concept of an external stimuli triggering the release 
of drug substances from the chamber. However, while magnetically 
actuated device has fast response time, the other devices need a few tens 
of seconds for the release of substance to begin. Again the proposed 





Figure 4-3. Comparison with other active drug delivery device. 
 
 
4.4. Integration with PDMS Electrodes 
 
This drug delivery device has another advantage. This device is fully 
made with only PDMS and a mixture of PDMS and metal particle 
composite. For this reason, integration with PDMS based electrodes can 
be easily achieved. PDMS based implantable neural electrodes and drug 
delivery system’s integration is important since inflammation reduction 
is a crucial factor to increase the duration of the electrodes. PDMS based 
neural electrodes can be implanted in the body on neural tissues for 
recording and stimulating neural activity. As the use of the electrode’s 
duration increase to days, weeks or months, gliosis may occur. Gliosis is 
a reactive change of glial cells in response to the damage to the central 
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nervous system. When not treated, gliosis can form glial scar. Even with 
PDMS electrodes, when chronically implanted, gliosis can occur within 
weeks after installation. Usually, neural recording and stimulating 
electrodes have a fixed impedance. This impedance value is crucial for 
the signal from the electrodes to be consistent over a long period of time. 
When gliosis occurs on the contact areas the impedance of the electrode 
to tissue increase and the signal extracted from the electrode will be 
different. Integration with drug delivery devices can be a solution. Many 
researches are in progress where synthetic steroids such as tibolone can 
suppress the growth of gliosis and scar tissue [136]. Tibolone can be 
soluble in dimethyl sulfoxide (DMSO) with 15mg/mL. Therefore, liquid 
substance delivery can also be possible. 
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의료 분야의 발전에 따라 수많은 약들이 개발되어 왔지만 아직까지 
투여 방법은 경구 투여 방법과 정맥에 바로 주입하는 주사기를 통한 
방법으로만 지속되고 있다. 경구 투여와 정맥 주사는 투여 방법이 
쉽다는 이유 때문에 아직도 주로 쓰이지만 특정 부위 또는 목표 
세포에만 약물을 전달하는 것은 어렵다. 효율적인 약물 전달은 
최소독성혈중농도 (MTC) 와 최소유효혈중농도 (MEC) 사이를 
유지하도록 약물을 적정량 그리고 적정 기간을 두고 전달해야 한다. 
현재에도 흔히 쓰이는 약물 전달 방식은 이러한 효율적인 약물 요법의 
조건들을 만족하지 못한다. 그러므로 경구 투약이나 주사에 의한 투여 
방법의 단점들을 보완할 수 있는 약물 전달 기기들이 활발히 연구되고 
있다. 
국소 부위에 설치하는 약물 전달 기기들은 약물 전달이 필요한 
부위에 설치되는 방법으로 공간적인 제어를 실현한다. 이러한 전달 
기기들이 만족해야 하는 조건들은 적정량의 약물, 정확한 시간에 그리고 
저전력으로 구동이 가능해야 한다는 것이다. 이 모든 조건들은 대부분의 
약물 전달 기기들이 가지고 있는 밸브와 펌프를 통해 달성할 수 있다. 
본 논문에서 제안하는 약물 전달 기기는 풍선과 같이 부풀고 수축이 
가능한 약물 저장소 구조를 제작하는 방법을 제안하여 전력이 필요한 
펌프가 없이도 약물 전달이 가능하게 하였다. 이 펌프는 자기장 혹은 
전자기장의 유무에 따라 구동되는 밸브를 만들어 약물 전달은 이 밸브를 
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열고 닫는 것만으로 가능하게 하였다. 이 밸브는 평상시에 닫혀 있는 
형태로 열릴 때만 전력을 사용하여 전력 사용량을 최소화 하였다.  
이 약물 전달 기기의 제작은 Polydimethylsiloxane (PDMS) 와 
PDMS 와 금속 기반의 마이크로 입자의 합성물로만 이루어지도록 
하였다. PDMS 패터닝은 일반적으로 Micro Electromechanical Systems 
(MEMS) 의 포토리소그래피 (photolithography) 와 식각 (etching) 
방식을 통해 이루어진다. 하지만 이런 방식은 여러층과 복잡한 구조를 
만들려면 여러 단계 그리고 긴 시간 동안의 공정 시간이 필요하다. 본 
논문에서는 사진석판술이나 식각과 같은 결과를 낳을 수 있는 새로운 
PDMS 공정 방법을 산소 플라즈마 표면처리 (oxygen plasma 
treatment), 자기조립분자막 (self-assembled monolayer) 그리고 
폴리염화 비닐 시트지 패터닝을 사용해 약물 전달 기기 제작법을 
제안한다. 
자기조립분자막은 PDMS 와 PDMS 간의 접착이 이루어지지 않게 
하기 위한 막을 분자 단위의 두께로 제작하는 방법이다. 반대로 산소 
플라즈마 표면처리는 PDMS 간의 접착이 더 효과적으로 이루어지게 
하는 방식이다. 자기조립분자막과 산소 플라즈마 표면처리를 조합하여 
폴리염화비닐 패턴을 통해 선택적 표면 접착을 실행하였다. 
폴리염화비닐 패턴은 칼로 잘라내는 자동 플로터 (blade plotter) 와 
레이저로 잘라내는 다이오드 펌핑 고체 레이저 (diode pumped solid 
state laser) 두 기기로 제작하였다. 선택적 표면 접착 방법은 약물 
저장소를 만드는데 사용하였다.  더 나아가, 폴리염화비닐과 PDMS 의 
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중합 억제 관련성을 조사하여 PDMS 식각을 실현하였다. PDMS 식각은 
약물 저장소와 밸브를 연결하는 마이크로 채널을 만드는데 사용하였다. 
이 약물 전달 기기의 약물 전달량은 기기의 약물 저장소의 크기, 막 
두께, 저장소를 빠져나가는 마이크로 채널의 단면적 크기 등 복합적인 
요소에 따라 달라진다. 약물 전달 시기를 제어하는 것은 자기장 또는 
전자기장을 통해 구동되는 마이크로 밸브이다. 이 밸브는 저전력 구동이 
가능하도록 평상시에는 닫혀 있도록 설계되었다.  
약물의 전달 시기를 조절하는 밸브는 외부 자기장으로 구동 될 수 
있도록 제작되었다. 이 밸브는 얇은 니켈 마이크로 입자와 PDMS 로 
섞은 얇은 막에 네오디뮴 자석이 접합되어 있어 평소에는 닫혀있는 
상태를 유지하다 자기장으로 구동되어 당겨지는 힘에 의해 열리는 
구조를 가지고 있다. 자기 구동은 막이 당겨지는 방향으로 자석을 
위치시켜 밸브가 열리게 할 수 있다.  
마지막으로, 제작된 약물 전달 기기는 생체 적합성을 분석하기 위해 
용출물 실험과 세포 독성 실험을 진행하였다. PDMS 는 높은 
생체적합성을 가지는 물질로 판명된 물질이다. 하지만 PDMS 만 쓰지 
않고 금속 마이크로 입자를 섞은 PDMS 와 네오디뮴 자석도 
사용하였기에, 또 이 기기는 피부에 접합하여 사용하거나 약물이 
전달되어야 하는 체내에 설치하는 방식으로 사용 되기 때문에 생체 
적합성 실험을 진행하였다. 더 나아가, 이 기기의 중요한 구성 요소인 
밸브와 펌프의 내구성도 조사되었다. 반복적인 실험으로 약물 전달량의 
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